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The topic of this study is the application of modern medical technology to 
cardiovascular conditions. The main purpose of that research is to evaluate 
myocardium disorders from the versatile perspectives and propose the design of a 
socially-demanding and financially-efficient technological solution targeted to 
coronary artery disease (CAD) diagnosing and monitoring. Phonocardiography 
and audial CAD detection are discussed as innovative methods for personalized 
healthcare applications and based on that, digital product design is developed in 
the form of functional specification, wearable device model, iOS and WatchOS 
applications interface architecture. 
 
In addition to the diseases study, myocardium signals acquisition discussion and 
to device design itself, market research is conducted. It is focused on medical 
technologies segment in general and cardiological systems in particular. Finland 
and Nordic Europe are the major covered regions, while global trends are outlined 
to collect the vision on the general market tendency. Core assessment topics are 
medical technology product distribution models, investment potential and 
development barriers. 
 
The final result could be used as a foundation for further product development and 
as an overview or guidelines for businesses interested in healthcare Internet-of-
Things and cardiological systems. 
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INTRODUCTION 
Cardiac conditions are the major cause of lethality in the world for the last numbers of 
decades. According to the European Cardiovascular Disease Statistics report from 2017, 
prepared by the European Heart Network (EHN), approximately 45% of all deaths in 
Europe are the result of the cardiovascular diseases (CVD). Even taking into 
consideration the fact that the rates of the diseases of that type are significantly 
decreasing, comparing to the end of 20th century, the numbers are still enormous, and 
that issue is in the major focus of healthcare organizations all around the world. [1] 
Three primary types of CVD are coronary artery disease (CAD, co-called ischemic heart 
disease, or IHD), arrhythmia and hypertension (the increased blood pressure). These 
conditions may result in the ischemic or hemorrhagic strokes, myocardial infarction (MI), 
heart failure and other health degradations affecting the quality of life. 
In addition to the notable mortality rates caused by CVD, for the last decade, a notable 
decrease in the patients' age is detected, what makes the current situation critical and 
solution demanding [1]. It is already known that diagnosis and prevention are the main 
research focus areas, as CVD early detection is a task of paramount importance, to 
produce a proper treatment plan to avoid the irreversible or even lethal consequences. 
Research organizations, like universities and medical institutes, are tightly working with 
such monitoring and diagnosing solutions, focusing on data collection and analysis, 
however, that appliances are far from being in production at that phase, while enterprises 
have been refusing to participate in such projects for a long time because of lack of 
specific technical knowledge in that sector and diffused business and marketing models. 
Therefore, addressing that question on local and international levels is not supported with 
the required investments, making the CVD detection interconnected systems appearance 
pace not as dynamic and ubiquitous, what on its turn does not allow to fight heart 
conditions smartly and efficiently. 
The purpose of that study is to evaluate critical heart conditions from the versatile 
perspectives and propose the design of a socially-demanding and financially-efficient 
technological solution to a single disease or a group of them. 
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Global CVD statistics 
Each year CVDs cause 17.9 million deaths globally, according to World Health 
Organization (WHO) statistics [2], what is almost a one-third of all lethal cases, what 
means that CVDs’ mortality rates exceed the values of cancers, HIV and any other 
communicable or non-communicable condition. In 2017, 3.9 million and 1.8 million 
people died from CVDs in European region and European Union (EU) respectively. It 
accounts for 45% of all deaths in Europe. Figure 1 depicts annual number of deaths in the 
world by cause in 2018, where the negative leading position of CVDs are easily 
noticeable. 
 
FIGURE 1. Global share of deaths by cause in 2016. [3] 
On the other hand, if we take a look on the past 60 years, the tendency of the CVDs’ 
mortality is positive, what means that mortality is falling almost in all European countries, 
even in Central and Eastern Europe, where an increase of CVDs was observed in the end 
of previous century. However, in addition to mortality rate, which is not a standalone and 
optimal measure, as living with CVD is also a complexity,  the amount of people suffering 
from CVDs is even more dramatic – in 2015, around 85 million people were living with 
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some sort of cardio-vascular condition in Europe, while 11.3 million of new cases were 
registered, 6.1 million of which are falling on EU, what shows, according to history, that 
for the last 25 years the absolute number of CVD cases increased. [1] 
If age studies are considered, CVDs show a tendency to affect younger segment of the 
population each year, enlarging the amount of registered cases in people under 35, what 
is mainly caused by the eating habits, sedentary lifestyle and smoking: 
• Smoking remains a key health issue in Europe and the previous tobacco 
consumption reduction temp has slowed down, while smoking among women is 
increasing, especially in Northern Europe; 
• Only a small number of European adults fulfil the recommended amount of 
physical activities, while average person from Northern Europe perform notably 
better comparing to Western and Eastern Europe; 
• Obesity levels are high all-over European countries in children and adults. 
Finally [1], cardio-vascular conditions are the cause of approximately 64 million DALYs 
(disability-adjusted life year, metric of the overall disease burden used internationally) 
loss, what is equal to 23% of the total DALYs lost in the European countries.  
All of the abovementioned numbers are unavoidably causing extra financial costs for 
healthcare and treatment sector, insurance, social compensations and similar needs, what 
is estimated to be around EUR 210 billion each year in EU since 2017 [1]. It is the main 
economic cost with the following breakdown: 
• EUR 111 billion for the healthcare costs; 
• EUR 54 billion for the productivity waste coverage; 
• EUR 45 billion for the unofficial CVDs handling. 
Two main causes of cost are CAD and stroke, which result in EUR 59 billion and EUR 
45 billion respectively. To compare, total CVD costs in EU in 2011 were only EUR 111 
billion, what is almost twice less comparing to nowadays. 
To sum up, CVDs are a number one priority question of the European healthcare and 
economy, while for the citizens heart diseases are a relevant wellbeing risk, which is not 
managed and accessed properly yet. Of course, governments are actively working on the 
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action plans and attempt to fight cardio-vascular conditions illiteracy among people, 
harmful habits to increase the general health of the nations, but the existing ecosystem in 
use does not apply the breakthrough technologies wide and well enough to change the 
CVD statistics.  
CVD in Finland 
Northern Europe is the leading region in the question of fighting the heart disorders, as it 
was slightly highlighted in the previous chapter, what is also seen from financial reports 
created by the EHN [1] – CVD costs per capita are EUR 365 in Finland (maximum value 
in EU in 2017), comparing to only EUR 48 in Bulgaria. Also, social polls show that 
Finnish citizens are aware of the heart diseases problem and attempt to control the dieting 
and activity levels. Similar situation could be observed in the neighboring Sweden, 
Denmark, Norway and Iceland.  
There is no doubt that the smart cardio appliance is a socially-demanding and financially-
attractive campaign (in terms of existing costs cuts and future sales) in Finland, while in 
order to aim the correct auditory (correct cardio-vascular disorder) and propose a new 
cheap solution with medically well-defined and technologically possible features, local 
healthcare situation should be studied first, what is overviewed in this chapter. 
History 
According to the report by Pekka Puska [4], in the beginning of 1970’s, CVD death rates 
were enormous in Finland, namely they have been the biggest comparing to the rest of 
the world – almost 800 and 400 deaths per 100000 of population in men and women 
respectively. Such a situation became the cause of the special national project 
development, named North Karelia project after the region with the most critical situation. 
The main aims and objectives of North Karelia project were: 
• Smoking reduction; 
• Cholesterol levels reduction; 
• Increased arterial pressure reduction. 
The programme included a close collaboration between medical service providers, mass 
media, food industry and a variable set of local non-government organizations (it shows 
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a clear Finnish experience in tight relationships between government and business 
organizations in the social questions). 
After the project piloting for 5 years, it was applied on the national levels. Studies and 
disease registers analysis conducted in 1995 shows a huge reduction in the risk factors, 
associated with the cardiovascular conditions, what on its turn provided a positive impact 
on the mortality and morbidity rates – for example, CVD death rates in 35-60 year-old 
men decreased by 65% across the country. In addition to the initial goals, general national 
health improved, positively affecting cancer statistics, for instance. 
Currently, the project is officially terminated, however the same approach and 
methodologies are still used in Finland to deliver a healthy lifestyle trends and basics to 
citizens. Moreover, this practice is widely used internationally, according to WHO 
reports. 
Current numbers and conclusions 
Historical statistics evaluation showed that Finland is well-acquainted with the CVD 
problem, however what is the current situation and what kind of problems heart 
conditions cause to the citizens in 2019? According to the Finnish Statistics institute [5], 
coronary artery disease resulted in every fifth death in 2017 (it is the most actual 
conducted study to the date). Even taking into consideration the fact that over the last 20 
years, the CVD mortality rates in Finland decreased from 44 to 36 percent, solely CAD 
caused 10000 lethal cases in 2017. Figure 2 depicts the age eliminated CAD lethality rates 
tendency for men and women. 
Considering age studies, currently one out of ten deaths caused by CAD are occurring in 
the working-age individual, however if we evaluate disease registers, six out of ten newly 
observed patients are of the working age, what means that this group is a potential 
auditory for detection and monitoring devices. 
Following conclusions are made based on the global and regional CVD studies: 
1. CVD in general is number one problem around the world, however Northern-
Europe, including Finland, has the lowest current death rates, both in men and 
women; 
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2. Notable amount of heart conditions patients is observed and monitored in Finland 
and the rest of Northern-Europe by healthcare providers; 
3. Finland has a versatile experience in fighting CVD; 
4. Because of the existing economical closeness of Finland and Scandinavian 
countries, Iceland, these countries could be considered as possible markets for the 
developed product. In other words, same marketing campaigns and development 
models could be used, while regulations are very similar also; 
5. Ischemic heart disease is the central focus from the statistics perspective. If deeper 
diseases research shows that this disease could be assessed using some existing or 
potential technological stack, it should be considered as a target condition for the 
product design stage; 
6. Age studies in Finland show that CVD are currently common in adults, while 
highest mortality rates are noticed in elders, what means that the developed 
appliance should target a variety of users with different experience in digital 
solutions. From the other hand, a smaller audience could be selected at first, as 
the methods may vary dramatically. Adults (22-55 years old) group is the optimal 
auditory.  
In addition to the abovementioned facts, following reasons make Northern Europe and, 
especially Finland, an optimal region for the innovative CVD product release and 
development: 
• Social awareness of the heart health importance; 
• Climate and environmental quality; 
• High average income and social payments system; 
• Tight collaboration between government and profit organizations; 
• Healthy lifestyle trend; 
• Technological literacy of citizens and computing technologies trust. 
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FIGURE 2. Age-eliminated CAD lethality rates tendency for men and women in 
Finland, 1971-2017. 
All in all, conclusions allow to suppose that the developed e-health product would evolve 
faster in Finland and Northern Europe comparing to other regions, its marketing would 
be easier, while social acceptance and possible government support will extend its 
applications to the wide levels. 
Medical approach transformation and global healthcare trends 
As cardiovascular conditions are selected as a discussion topic, ways of development of 
the modern medicine and the technological problems that it faces should be studied and 
highlighted, because healthcare system is a solid mechanism, where diseases are 
interconnected, and methodological approaches are universal. This chapter reflects the 
modern medicine improvement vectors. 
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In order to analyze how technologies are applied for treatment and diagnostics, let’s first 
evaluate how this system has been changing for the last centuries. Medicine paradigms 
are the following: 
• Treatment medicine 
o Treatment which is based on clearly defined protocols regardless the 
particular case. This practice is no longer used widely. As we speak about 
Europe as a whole, it is not embedded to the existing stack of healthcare 
methods; 
o Evidence-based medicine, which is currently a standard all over the 
developed countries; 
• Predictive medicine 
o Treatment and preliminary condition influence based on the collected data 
analysis. This approach is increasing in popularity, all the existing 
telemedicine systems are targeted to collect some data, structure it and 
locate some patterns in order to select a proper treatment plan; 
o Completely predictive medicine – this paradigm is a vision for the future. 
Predictivity is highly based on data and ways how it is handled, 
consequently predictive medicine approach could be considered as a 
whole for now, while its stages are not relevant for this discussion. 
It is clear that different medical approaches require different tools, what means that core 
market players will change steadily. As for the current evidence-based medicine, 
pharmaceutical companies are the core unit, while in predictive approach technological 
companies, medical service providers and insurance companies will form a responsible 
alliance. Figure 3 shows the medicine development vectors infographics. 
As mentioned previously, predictive medicine is about information, what means that 
everyone’s case and its data is going to be a part of the system. In other words, predictive 
approach implies a personalized healthcare, which allows: 
1. Rapid growth of the information base from the individuals – this makes the 
analyzes and patterns findings possible; 
2. The choice of treatment methods and drugs based on the individual characteristics 
of the patient. 
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FIGURE 3. Medicine paradigms development vector infographics.  
To sum up, currently medicine need tools targeted to personalized data collection, which 
allow to access different conditions. Such systems should include the following 
components: 
1. Data collection unit – a device which is developed to address exact disease or a 
set of them; 
2. Data processing unit – a subsystem where required data is normalized and 
streamlined, stored in some comparable and accessible format; 
3. Data analysis unit – a subsystem where data is calculated to find patterns based 
on the condition existing studies and pathogenesis, as a result this unit provides a 
valuable insight for practitioners or even makes a final decision itself; 
4. Of course, the developed systems should have interfaces, so that users and medical 
service providers are able to access the results, control the process and so on. 
All this draws an idea of the digital connected healthcare, where wearables or implants 
are the data collection units, while machine learning, AI and neural networks are used to 
make the decisions providing the following core features of the future medicine: 
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• Automatized diagnostics; 
• Real-time anomaly and pathology detection with an instant decision making; 
• Automatized conclusion drawing and treatment plan preparation. 
Wearables and implants are already widely used in healthcare and professional medicine, 
however the devices targeted to these sectors are very different. The majority of the 
personal devices are cheap and used for the wellbeing applications, like sports and general 
monitoring. As for the professional devices, current market offers a variety of highly-
technological products applicable for medical applications, however these devices are not 
affordable for usual users both from the usability and financial perspectives. Moreover, 
they lack that system consistency described above, what also makes them inefficient.  
These discussions lead to a conclusion that the major barrier to solve in healthcare today 
is in its real personalization and connectivity, so that common people of any age-group, 
education and technological awareness may use something for advanced medical 
monitoring with a straight connectivity to the healthcare providers where patient’s data is 
aggregated in a structured way for the analysis. Cardiology is a great segment of 
healthcare, where such products could be developed, as it offers quite simple from the 
technical point of view biosignals acquisition methods, wide existing understanding of 
the diseases and ways to handle them and a an already studied initial patterns and flows 
of data with a huge number of possible improvements and new assessment techniques. 
Problem evaluation and statement 
It is surprising to discover, but the problem which affects the emergence of the proper 
cardiovascular diseases monitoring appliances and services is not caused by the technical 
barriers, as modern medical instrumentation, sensors, data handling and storage solutions, 
data processing and analysis techniques are well-known and nearly ready to be widely 
applied for CVD patients monitoring and alerting. The core problem has two parts as 
follows: 
1. Current market lacks any mass, usable and validated solutions targeted to address 
CVD issue truly in a personal manner, while personal approach is critical here, 
because heart state could be monitored to predict CVDs. All the existing solutions 
were created with the major attention on how to get the data and process it, not on 
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how to create a convenient product for the customer, which will actually work in 
practice. It comes from the fact that existing research is mostly sealed inside the 
medical and educational organizations; 
2. Local business organizations are almost not involved in the process because they 
do not have enough knowledge of medical devices for CVD monitoring, however 
the possible market share and revenue acquisition potentials are huge. Moreover, 
there is a business and product specifications unclearness complemented with 
strict regulations. On the other hand, current personal healthcare market targets 
sport and wellbeing applications with proper solutions by startups and enterprises  
quite well, making it as big as 70% of all wearables and other smart devices 
produced, what shows that health technology segment is interesting for non-
governmental organizations and that research and development power is ready for 
a more serious product. According to The Wearable Technology Ecosystem: 
2018-2030 - Opportunities, Challenges, Strategies, Industry Verticals [6], and 
Forecasts report, the wearable device market will grow at a CAGR (Compound 
Annual Growth Rate) of around 22% between 2018 and 2021. Unfortunately, this 
distinguished growth is based again on sports appliances and wellbeing services, 
while medical monitoring devices are just a small portion of it. 
To sum up, CVD problem is taken seriously, however, unfortunately, there is a lack of 
digital product, market segment, marketing and business models understanding, what 
hamper proper products releases, which will help to take critical CVD situation under 
control applying newest available technologies. 
Research questions and aims 
The purpose of this work is to overview the current situation with cardiovascular diseases 
from technological and business perspectives in order to prepare a necessary reference 
digital product design to address one or a group of selected conditions in Finland. 
Main research questions are the following: 
1. How medical technologies could be used in cardiology to improve it? 
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2. Which CVD is the most critical one? What is its pathogenesis and how it could be 
diagnosed and treated? How is it interconnected with other conditions and what 
are the ways to access them via the same appliance? 
3. What are the innovative ways of collecting cardiovascular system signals and how 
they could be analyzed to predict or control the selected condition?  
4. What kind of the user interface of the medical device is required, so that it could 
be used on daily basics? 
5. What kind of service ecosystem is required for the created product? 
6. Who is the target auditory for the cardiological devices? 
7. Which region is the optimal for the digital cardiological product release? 
8. What is the current medical technologies market situation in Finland and how a 
new medical device could be promoted to be profitable? 
Research aims are: 
1. Illustrate via example how to improve digital experiences that allow patients to 
conduct full stack of medical diagnostic as a part of their usual life rhythm. In 
other words, the problem to solve is the question on how to properly embed 
medical devices and systems to usual healthy life in order to prevent the disease; 
2. Increase the interest of businesses in medical devices and, specifically, CVD 
monitoring systems by providing clear guidelines on how to enter that market; 
3. Investigate what kind of innovative product design is required to address a 
selected CVD, prepare its specification, device concept and user-facing interface 
design; 
4. Illustrate possible development vectors for the created digital solution, reveal its 
weak points and discuss secondary possible applications. 
Research methodology and plan 
The topics covered in this study are not new, consequently existing documentary analysis 
is performed to collect the core materials for evaluation and discussions. All of the 
reviewed research papers, journals and articles are publicly available. Quantitative 
research techniques are used to evaluate current CVD in general and CAD in particular 
statuses and peculiarities.  
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Market research is conducted by the use of interviews and quantitative analysis of 
organizations’ annual reports, enterprises overviews of the segment. Based on the 
conducted market study conclusions, product offering possibilities are outlined, what in 
turn in addition to technological research results in user stories and product functional 
design. 
Research plan and milestones are depicted in the mind map, attached in Appendix 4. 
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CHAPTER 1: Cardio-vascular diseases (CVD) 
CVD is a very versatile group of disorders, from which only a part is the cause of the 
extreme mortality rates in Finland. In this chapter, the most common cardiovascular 
diseases are discussed and classified from the physiological, diagnosis perspectives (the 
medical treatment itself is out of the scope of the document, as it is irrelevant in terms of 
condition detection and analysis). The pathogenesis studies of the conditions selected, 
according to the medical statistics presented in chapter CVD in Finland, will be used to 
draw conclusions about focus condition selection, which on its turn will be the basis for 
the appliance design and feature specification, presented in the section CHAPTER 4: 
CAD diagnostic system functional specification and design. 
Coronary artery disease (CAD) 
According to statistics, in Europe ischemic heart disease (IHD) or, co-called coronary 
artery disease (CAD), and cerebral stroke (see chapter Stroke) identify 85% of all diseases 
of the cardiovascular system [2], which characterizes CAD as one of the most common 
diseases. CAD is a chronic disease caused by atherosclerotic sediments in the coronary 
arteries, which lead to a narrowing the affected vessels, the so-called coronary stenosis. 
Coronary stenosis, in turn, causes impaired blood supply to the myocardium (heart 
muscle). Atherosclerotic sediments can affect not only the coronary arteries, but also 
microvessels, making them rigid and inelastic, therefore the influx of oxygen-enriched 
blood to the myocardium is significantly reduced. Blood supply to the heart muscle can 
also be affected by the large spasms and blockage of small blood vessels. Stenosis 
(narrowing) at the same time can be subject to one or more coronary vessels.  
Chronic coronary insufficiency is associated with a slowly increasing coronary artery 
stenosis and is manifested by attacks of angina pectoris (clinical syndrome characterized 
by a feeling or discomfort behind the sternum). The pain appears suddenly during 
physical exertion or emotional stress, after eating, usually radiating to the left shoulder, 
neck, lower jaw, between the shoulder blades, the left subscapular region and lasts no 
more than 10-15 minutes [7]. Acute coronary insufficiency caused by a sudden violation 
of coronary blood flow, may be the cause of the development of myocardial infarction 
(see chapter Myocardial infarction (MI)). [8] 
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The prognosis of CAD is conditionally unfavorable, the disease is chronic and steadily 
progressive, the treatment only stops or significantly slows its development, but does not 
reverse the disease, what means that the earlier the condition was detected, the easier the 
stable state maintaining for the patient is. 
CAD: Classification and clinical forms 
Nowadays, CAD is classified by clinical forms, each of which has independent 
significance in view of the characteristics of clinical manifestations, prognosis and 
treatment tactics. The following classification was recommended in 1984 by a group of 
WHO (World Health Organization) experts: 
1. Sudden coronary death (primary cardiac arrest) 
a. Sudden coronary death with successful reanimation; 
b. Sudden coronary death (lethal); 
2. Angina pectoris (or simply Angina) 
a. Stable angina pectoris; 
b. Coronary syndrome X; 
c. Vasospastic angina pectoris; 
d. Unstable angina pectoris 
i. Progressive angina pectoris; 
ii. First-time angina pectoris; 
iii. Early post-infarction angina; 
3. Myocardial infarction; 
4. Cardiosclerosis; 
5. Painless form of CAD; 
6. Arrhythmia. 
All the above-mentioned CAD types are the area of preliminary monitoring, especially 
the painless form of CAD, myocardial infarction and unstable angina pectoris, as these 
three types show less stable and noticeable or even none of clearly definable symptoms 
at some stages.  
Next, the most relevant clinical forms overview is presented [7]: 
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1. Angina is characterized by the chest pain, which is caused by any factor leading 
to the increased blood pressure or tachycardia (elevated heart rate). The pain 
attack of stable angina is usually does not exceed the time interval of 30 minutes. 
Also, it stops almost immediately, after sublingual intake of drugs containing 
glycerol trinitrate. That fact could be used as a diagnosis index, which reflects the 
critical need of the cardiologist visit. The diagnosis of stable angina is established 
in cases of a stable manifestation of the disease in the form of a regular occurrence 
of pain attacks, ECG changes preceding an attack on a certain level of load for at 
least 3 months. Other occurrences of angina could be diagnosed as: 
a. Angina stress – non-stable manifestation of chest pain; 
b. Initial angina – diagnosis is established in case of firstly detected 
manifestations of angina; 
c. Progressive angina – is characterized by a rapid increase in the frequency 
and severity of the pain attacks; 
d. Spontaneous angina – pain attacks are not caused by factors, leading to the 
expanded metabolic needs of the myocardium; 
e. Variant angina – cases of spontaneous angina, accompanied by transient 
elevations on the ECG of the ST segment [9]; 
2. Myocardial infarction – see chapter Myocardial infarction (MI); 
3. Cardiosclerosis – the diagnosis of post-infarction cardiosclerosis as an 
independent clinical form of coronary artery disease is established if angina and 
other forms of coronary artery disease are not available for the patient, but there 
are clinical and ECG signs of focal myocardial sclerosis: 
a. Persistent arrhythmias; 
b. Conduction; 
c. Chronic heart failure; 
d. signs of myocardial scarring on ECG; 
4. Arrhythmia – see chapter Heart arrhythmia. 
CAD: Pathogenesis  
The formation of atherosclerotic plaque occurs in several stages. At first, the vessel does 
not change significantly. As lipids accumulate in the plaque, gaps in its fibrous cap 
appear, which is accompanied by the deposition of platelet aggregates that contribute to 
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the local deposition of fibrin. The area of the wall thrombus is covered by the newly 
formed endothelium and protrudes into the vessel, narrowing it. Along with lipidofibrous 
plaques, fibrous stenotic plaques are formed, which are subjected to calcification. As 
plaques enlarges and their number increases, the degree of stenosis of the coronary 
arteries extends, largely determining the severity of clinical manifestations and the course 
of CAD. The narrowing of the artery up to 50% is often asymptomatic. Usually clear 
clinical manifestations of the disease occur when the it is narrowed up to 70% or more. 
However, even the hidden symptoms are observable by the use of heart monitoring 
techniques, described in chapters CHAPTER 2: CAD common detection methods and 
their limitations and CHAPTER 4: CAD diagnostic system functional specification and 
design, what means that the preliminary treatment steps could be taken well in advance. 
CAD: Etiology 
Epidemiological studies have proposed various models for classifying the multiple risk 
factors associated with CAD. Risk indicators can be classified as follows [10]: 
1. Biological determinants 
a. Elderly age; 
b. Male; 
c. Genetic factors that contribute to dyslipidemia, hypertension, glucose 
tolerance, diabetes and obesity; 
2. Anatomical, physiological and metabolic (biochemical) determinants 
a. Dyslipidemia (abnormally elevated levels of lipids and lipoproteins in 
human blood); 
b. Arterial hypertension (see chapter Hypertension); 
c. Obesity and the nature of the fat distribution in the body; 
d. Diabetes (increased levels of glucose in blood); 
3. Behavioral factors that may exacerbate coronary artery disease, but could not be 
the alone determinants 
a. Eating habits; 
b. Smoking; 
c. Lack of physical activity; 
d. Physical activity exceeding the adaptive capacity of the body; 
 
 
 
22 
e. Alcohol consumption. 
Myocardial infarction (MI) 
Myocardial infarction (MI or heart attack) - necrosis of a part of the heart muscle as a 
result of acute occlusion of the coronary artery. As mentioned in the previous section, MI 
is one of the clinical forms of coronary heart disease, in fact, it could be considered as 
CAD consequence. The most common cause (98%) of cessation of blood flow is 
thrombosis, which develops when an unstable atherosclerotic plaque is damaged. As a 
result of prolonged ischemia of the heart, necrosis develops with the formation of a 
leukocyte shaft at the edges. Further phagocytosis is formed, a scar is formed. [11] 
Sometimes, terms STEMI and NSTEMI are used to describe different types of myocardial 
infarction. STEMI (ST-segment elevation) refers to the MI caused by a full coronary 
artery blockage, while in case of NSTEMI (non-ST-segment elevation) the artery is 
blocked partly. Usually, clinically significant is the narrowing of the arterial lumen of the 
heart to such an extent that the restriction of the blood supply to the myocardium can no 
longer be compensated. STEMI form is considered to be a more severe. [12] 
MI: Clinical picture and atypical forms 
The main clinical sign is intense chest pain. However, the pain can be variable in nature. 
The patient may complain of a feeling of discomfort in the chest, pain in the abdomen, 
throat, arm, scapula. Often the MI is completely painless, what is very usual for patients 
with diabetes. In 20-40% of cases with large-focal lesions signs of heart failure (see 
chapter Heart failure) develop. [13] 
Often MI is accompanied by arrhythmias (see chapter Heart arrhythmia). It could be 
various forms of premature beats or atrial fibrillation. Often, the only symptom of 
myocardial infarction is sudden cardiac arrest. The usual predisposing factors of MI are 
notable physical activity, psycho-emotional stress, fatigue, hypertensive crisis. [11] 
In some cases, the symptoms of myocardial infarction may be atypical. This clinical 
picture makes it difficult to detect the MI by the patient and the physician. The following 
atypical forms of MI are distinguished [11] [14]: 
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• Abdominal form – symptoms are represented by pain in the upper abdomen, 
hiccups, bloating, nausea, vomiting. In this case, the symptoms of MI may 
resemble the symptoms of acute pancreatitis; 
• Asthmatic form – symptoms are represented by increasing breathlessness and 
resemble the symptoms of an asthma attack; 
• Painless myocardial ischemia – it is rarely observed. This development of 
infarction is most characteristic of patients with diabetes; 
• Cerebral form – symptoms are represented by dizziness, impaired consciousness, 
neurological symptoms; 
• Collaptoid form - begins with the development of collapse; the clinic is dominated 
by sudden hypotension, dizziness, cold sweat, darkening of the eyes. Regarded as 
a manifestation of cardiogenic shock; 
• Peripheral - is characterized by localization of pain not in the chest or precardiac 
region, but in the other regions; 
• Edematous - the patient has shortness of breath, weakness, edema relatively 
quickly, and even ascites, the liver increases - that is, acute right ventricular failure 
develops. 
Heart arrhythmia 
Heart rate arrhythmia is a pathological condition [15], leading to a change of the 
frequency, rhythm and sequence of excitation and contraction of the heart. According to 
WHO, arrhythmia is any heart rhythm that differs from normal sinus rhythm. In this 
pathological condition, the normal contractile activity of the heart can be significantly 
disturbed, which, in turn, can lead to a number of serious complications.  
Arrhythmia: Etiology 
This section outlines the most common causes of cardiac arrhythmias and conduction 
disorders [15]: 
1. Cardiac causes 
a. Coronary artery disease, including myocardial infarction and unstable 
stenocardia; 
b. Heart failure; 
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c. Cardiomyopathy; 
d. Acquired heart defects; 
2. Medicinal effects (cardiac glycosides, antiarrhythmic drugs, diuretics); 
3. Electrolyte disorders (hypokalemia and hyperkalemia, hypomagnemia and 
similar); 
4. Toxic effects 
a. Smoking (nicotine effect); 
b. Narcotic substances; 
c. Alcohol; 
d. Thyrotoxicosis; 
5. Idiopathic forms of arrhythmias are caused by the unknown factors. These 
arrhythmias are often discoverable, moreover, their cardiac effects and 
manifestations are the same, consequently the detection of such hidden and 
inexplicable forms is very relevant. 
Arrhythmia: Pathogenesis 
Under the influence of one or several etiological factors described in the previous section, 
one or several functions of the heart are disturbed: 
1. Automatism – automatic pulse generation by sinoatrial node; 
2. Excitability – the ability of cardiomyocytes to generate action potential in 
response to irritation; 
3. Conduction – conduction of the pulse through the cardiac conduction system; 
4. Contractility – contraction of contractile cardiomyocytes; 
5. Refractoriness – electrical inertness for some time after the impulse, preventing 
the return of the conducted impulse and the imposition of the next; 
6. Abberantness – the possibility of impulse to spread along additional pathways of 
the cardiac conduction system. 
As it is seen, the basis of arrhythmia is a change in the conditions of the formation of 
excitation of the heart muscle or an anomaly of the ways of its spread. Arrhythmias can 
be caused by both functional disorders and severe organic lesions of the heart. A certain 
role in the occurrence of arrhythmia plays the state of the nervous system. Emotional 
stress causes changes in pace, and often in the rhythm of heart contractions, even in 
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healthy people. Arrhythmia often occurs in people with diseases of the central and 
autonomic nervous system. 
The understanding of arrhythmia pathogenesis is critical for evaluation of monitoring 
techniques and the subsequent analysis, as exactly that CVD collects a variety of forms 
with specific electro-cardiac peculiarities visible on ECG, which is the primary diagnosis 
method, combined with the versatile lifestyle factors. 
Arrhythmia: Classification 
According to U.S. National Heart, Lung and Blood Institute, the most common types of 
the heart rate arrhythmia are [16]: 
1. Bradyarrhythmia (or Bradycardia) – such a change in the heart rate, in which there 
is a decrease to 30-50 beats per minute, due to a decrease in the automatism in the 
sinoatrial node. If the rate reduction is not significant, then this does not represent 
a danger. But on the other hand, such changes can serve as the first signal of the 
onset of some pathological process in the body by other organs and systems (for 
example, a change in the function of the thyroid gland). If the frequency of heart 
decreases dramatically, the risk of sudden cardiac arrest increases. In severe forms 
of bradycardia, the pacemakers are installed; 
2. Ectopic heartbeat – small mostly harmless changes in the heart rate, leading to the 
skipped or additional beats. The most common forms are Premature ventricular 
contractions (PVC) and Premature atrial contractions (PAC). This form of 
arrhythmia is out of the scope of this study, as in the majority of cases it could not 
be considered to be critical for the patients’ health; 
3. Supraventricular arrhythmias – it is always a form with a tachycardia. The 
arrhythmias of that type are originating from the atrium or the gateway to the 
lower chambers: 
a. Atrial Fibrillation (AF); 
b. Atrial Flutter (AFL); 
4. Ventricular arrhythmia – the forms of that type are originating in the lower 
chambers: 
a. Ventricular tachycardia; 
b. Ventricular fibrillation. 
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To summarize the variety of arrhythmias, all types of bradycardia, tachycardia, AF and 
AFL are the aims of continuous monitoring appliances. 
Atrial Fibrillation (AF) and Atrial Flutter (AFL) 
At the basis of the emergence of AF and AFL there are similar etiological factors and 
pathogenetic mechanisms. Atrial Fibrillation is the most common arrhythmia form, which 
is characterized by chaotic electrical activity of the atria with a pulse frequency of 350-
700 beats per minute, which eliminates the possibility of the coordinated reduction. The 
chronic AF leads to an increase in the risk of death of approximately 2 times, what makes 
this condition very critical.  
In Atrial Flutter, pathological excitation occurs from a lesion located in the atria. As a 
result, the rhythm remains correct, but its frequency increases from 200 to 400 beats per 
minute. The ventricles do not contract as often as the atria, because they do not always 
receive the excitation wave. 
To sum up, arrhythmia is a very popular condition and as mentioned in Coronary artery 
disease (CAD) section, some occurrences of angina could be caused by arrhythmia. As a 
result, arrhythmia should be for sure considered as a condition to be assessed in the 
appliance, even if it is not the major aim condition of the product. Basic ECG 
(electrocardiogram) is the method for the arrhythmia diagnosis. If the coronary artery 
disease is selected as the primary monitoring and diagnostic condition of the final product, 
ECG is not a data acquisition option, however ECG still needs to be taken for CAD 
analysis, so arrhythmias could be a proper extension to the system. See CHAPTER 4: 
CAD diagnostic system functional specification and design for more details.   
Hypertension 
The concept of arterial hypertension denotes an increase in the blood pressure [17]. 
Hypertension is one of the most popular cardiovascular conditions and it affects the same 
organism parts as CAD. Moreover, it is clear that narrowing of the coronary artery affects 
the blood pressure levels locally, what should be strongly separated from the hypertension 
itself. 
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The main pathogenetic factor of hypertension is not the organic change of the vessels, so-
called, atherosclerosis (see Coronary artery disease (CAD) section for more details), but 
functional impairment. It is mainly expressed in the increased tonic contraction of the 
arterioles of the whole organism.  
As we evaluate different stages of the hypertension, following classification is widely 
used: 
1. No hypertension: normal blood pressure at the average adult – 120/80 (where first 
set of numbers stands for a range of systolic (direction from heart) pressure and 
the second group of numbers means diastolic (direction to heart) pressure); 
2. Soft stage – 140-179/90-100; 
3. Moderate stage – 180-199/105-114; 
4. Severe stage – 200/115 and more. 
An important addition to hypertension in terms of CAD, is that on the late phases of the 
hypertension, the organic changes in the form of arteriosclerosis occurs. It becomes the 
most important supporting factor in the development of the disease. Under the influence 
of hypertension, atherosclerosis of large arteries rapidly develops, as a result of which the 
blood supply to the most important organs is getting worse, what is a direct manifestation 
of CAD and possible MI. 
Nervous system is highly influential in the process of the hypertension development. The 
elimination of stress factors in some cases lead to the complete normalization of elevated 
blood pressure levels and the cessation of the disease process. In turn, it prevents the 
further condition transformation to CAD. 
Hypertension, like any chronic CVD is easier to prevent than to cure. Therefore, the 
prevention of hypertension is the task of paramount importance. Proper lifestyle and 
regular monitoring help to delay or prevent the hypertension from developing. It means 
that hypertension should be taken into a consideration in the final appliance.  
Heart failure 
Heart failure is a clinical syndrome that is a complication of heart diseases and is 
characterized by progressive systolic and diastolic dysfunction of the ventricles of the 
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heart with the formation of inadequate tissue perfusion and a decrease in exercise 
tolerance. In other words, heart is not capable of the release of blood necessary to maintain 
the organism’s metabolic needs. Heart failure is not an initial heart condition, but it is a 
consequence of different CVDs or other medical factors. The direct remote diagnosis is 
complicated with the wearable devices; however, its manifestations could be detected. 
The etiology of the heart failure is the following [17]: 
1. CAD and myocardial infarction – 40% of the heart failure cases are caused by 
these conditions; 
2. Hypertension – 35% of the heart failure occurrences; 
3. Other variable conditions and toxic effects on heart. 
It is clearly seen that CAD and hypertension are the main cause of the heart failure, what 
makes them a complex system of tightly combined cardio-vascular diseases, which 
should be monitored and considered together, as well as arrhythmias. 
Stroke 
Stroke stands for human brain cells necrosis, what could be compared to myocardial 
infarction, which is the necrosis of heart cells. Stroke is not a primary disease; it occurs 
as a result of a single or a set of cardiovascular conditions and is an important in terms of 
the CVD development and monitoring. 
Stroke is highly correlated with coronary artery disease - if the occlusion of a vessel with 
a blood clot or atherosclerotic plaque led to the death of brain tissue, then it is called an 
ischemic stroke. This type of stroke is the most common [18] - up to 85% of all reported 
cases are diagnosed as this type. Ischemic cerebral stroke is classified the following way: 
1. Thromboembolic. In this case, the source of the blockage of the vessel is the teared 
off atherosclerotic plaque. Also, embolism can occur with various injuries, 
operations to remove tumor formations and thrombophlebitis; 
2. Acute ischemic stroke of the hemodynamic type occurs with prolonged spasm of 
brain vessels. In such cases, the brain tissue does not receive enough nutrients. A 
similar condition occurs with high or low blood pressure; 
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3. Lacunar stroke is a consequence of the defeat of small arteries. It is manifested by 
impaired sensitivity and motility. 
Depending on how severe the ischemic stroke was, the consequences may be different. 
After a slight ischemic stroke, full recovery is possible. In this case, the person fully 
recovers his ability to move, talk and work. With significant neurological disorders, the 
patient’s ability to work is restricted. Often the disease is fatal. 
The second type of stroke is the hemorrhagic stroke. The main cause of it is the arterial 
hypertension. A hemorrhagic stroke is an acute disorder of the cerebral circulation 
resulting from the disruption of the integrity of the vessel and hemorrhage in the brain. 
From the point of view of localization, a stroke of this type can be parenchymal or 
subarachnoid. Among adults it occurs due to excessive physical exertion, injury or as a 
result of hypertensive crisis. The consequences of hemorrhagic stroke can be extremely 
serious. Annual mortality reaches 50-90%, as this condition is often complicated by 
swelling and displacement of the brain stem. 
To sum up, CAD, hypertension and arrhythmia are the core initial conditions to be 
monitored and analyzed to prevent the stroke. 
CVD clinical studies research conclusion and the target condition selection 
Consideration of the risk indicators from the Nordic countries’ perspective, shows that 
population is highly vulnerable to CAD and this condition is the most critical in that 
region. Also, according to cardiovascular diseases study, coronary artery disease is one 
of the primary conditions, leading to severe myocardial infarction and ischemic stroke. 
With no doubt, CAD is selected as the main target condition. 
If we evaluate the versatile CVD types, it is also seen that hypertension and arrhythmias 
are affecting the development of other diseases. Besides, these two conditions are highly 
interconnected and correlated with coronary artery disease. It means that the final solution 
should incorporate them as secondary target diseases. Complex of three mentioned 
conditions would provide a foundation for CVD management appliance. Also, such a 
combination is suitable in terms of target auditory, discussed in Market study conclusions, 
and detection methods. 
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CHAPTER 2: CAD common detection methods and their limitations 
This chapter discusses existing coronary artery disease detection methods, their 
limitations and peculiarities. This overview will lead to a selection of the possible method 
for CAD diagnosis in wearable solution. 
Nowadays, situation is so that all the major and used CAD detection techniques are very 
complicated and only possible for stationary application by professional medical 
specialist. These methods include: 
1. Angiography (coronary catheterization); 
2. Coronary computed tomography (CT) angiography; 
3. Magnetic resonance imaging (MRI); 
4. Cardiac stress test; 
5. Scintigraphy; 
6. Intravascular ultrasound; 
7. Biomarkers. 
Angiography is an invasive method of radiographic visualization of the coronary arteries 
lumen after selective intracoronary insertion of the contrast substance via catheter. 
Coronary angiography remains a standard in the diagnosis of CAD, as today it is the only 
existing method to determine the exact details of the anatomical structure of the entire 
coronary stream. In addition to diagnostic, same method is used as the only CAD 
treatment technology. In case the occlusions are detected, special stent could be placed to 
the coronary artery via the same catheter. This stent enlarges at the place of the plaque 
and makes the artery wider. Angiography is performed only in hospital and it requires 
several hours of complete rest and up to 1 day of monitoring in the medical organization 
after the procedure. [19] 
Coronary computed tomography angiography is quite similar to angiography, based on 
the nature of visualization. Yet the approach is very different. A CT scan makes a series 
of images of the heart, after which a three-dimensional image is built using a computer. 
Coronary vessels are distinguished, and their patency is determined based on these 
images. According to experts, CT coronary angiography allows to investigate the state of 
the heart vessels, the stent passage, measure the level of vascular calcification, obtain 
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heart function indicators, and all this within 40-50 seconds, without the need for 
hospitalization and anesthesia. The only invasive part is the contrast injection into the 
ulnar vein. This process and imaging itself are synchronized with a specific phase of the 
cardiac cycle. [20] 
MRI CAD detection technique is based on the obtaining images of the myocardium before 
and after the insertion of the paramagnetic contrast substances. Evaluation of myocardial 
mobility in this case in combination with obtaining delayed post-contrast images helps to 
assess myocardial viability as in patients with chronic CAD and acute myocardial 
infarction. This method is not applicable for patients with pacemakers, defibrillators – 
cardioverters, metal terminals on cerebral vessels, electronic prostheses of the inner ear, 
miostimulators and same implants. At the same time, MRI scanning is possible for 
patients after angioplasty, what means that the presence of stents is not restricting the 
procedure. [21] [22] 
Cardiac stress test technique uses ECG and other vitals monitoring under the effect of 
intensive training, so-called stress. This method is the most affordable and simple one, 
however it does not provide final and accurate results in terms of CAD detection. It is 
generally used as a pre-diagnostic tool and is always validated by angiography. [23] 
Scintigraphy is an almost non-invasive examination of the heart, which is often conducted 
under stress. During the procedure, a substance containing radioactive isotopes is injected 
into the patient's vein. The radiopharmaceutical circulates through the body and is 
absorbed by the myocardium. Then, using a gamma camera, its distribution in the heart 
muscle is analyzed. The concentration of isotopes determines the degree of blood supply 
to a particular area of the myocardium. In the zones of ischemia, the substance with 
radionuclides is poorly absorbed, what is clearly distinguishable in the taken images. [24] 
Intravascular ultrasound is an imaging technique which uses ultrasound for CAD 
investigation. The technique consists on carrying a small probe through the conductor 
into the lumen of the coronary arteries. An ultrasonic transducer is put to the site of the 
area under investigation. Next, the sensor is reversely traced. The ultrasonic sensor is 
connected to a special machine, on which the analysis of the obtained image is performed. 
Similar to angiography, this method is invasive, while it does not require the injection of 
the contrast due. [25] 
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Biomarker in general is any measurable substance that lead to understanding the condition 
of the human body. Recently, the development of fairly simple, but highly sensitive and 
specific markers of myocardial damage allowed the laboratory CAD analysis. Following 
markers belong to myocardial analysis: cardiotroponin (cTnT and cTnI), brain natriuretic 
peptide (BNP and NTproBNP), heart protein binding free fat acids (H-FABP), as well as 
risk markers for critical conditions in cardiology. The latter, along with indicators of 
lipoprotein metabolism, include a range of pro-inflammatory (hs-CRP) and other markers 
that characterize the instability of the artery wall in the area of atherosclerotic plaque, as 
well as the myocardial remodeling processes. [26] 
As it is seen, all the above-mentioned methods require high-priced equipment and the 
hospital setting. In addition, some of them are dated in terms of digital transformation and 
there is no way to rethink these methods to put them into a small wearable appliance. The 
most accurate and validated technique, angiography, is invasive, what makes it irrelevant 
for healthy myocardium monitoring. As for the promising biomarkers, it is impossible to 
take the sample and analyze it remotely. 
In the modern literature there is a least covered method applicable for diagnosis of CAD 
presence and possible heart structural and functional changes caused by it. This method 
is called audial detection, or phonography, and it uses sound generated by blood flow in 
the coronary artery to detect the condition. Technological simplicity, appliance 
compactness, non-invasive approach and low price make CAD audial detection a 
promising method for heart monitoring in personalized healthcare. More information on 
the measurement procedure and requirements are provided in the practical part of this 
study. See chapter Data collection and analysis for more details. If we evaluate the 
available products using audial detection, they are discussed in section Market of CAD 
and other cardiovascular digital solutions. 
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CHAPTER 3: Healthcare digital technologies market research 
This section reflects the results of the conducted market research in the digital healthcare 
segment and its aspects relevant for the cardiological digital systems. The study was 
performed by analyzing the reports and statistics, prepared by different consulting 
agencies and business research organizations and are relevant in terms of understanding 
the financial perspectives of the cardiological smart products globally and in Finland. The 
conclusions could be used to define the correct development models for the created device 
and the most efficient operations regions and auditory. 
In order to perform a proper investigation of the segment, it is crucial to define the 
differences between the terms, which are often used as interchangeable: 
• Healthcare is a general term, which is used to describe the processes of human 
health improvement and support via preventive measures, diagnosis and 
consequent diseases (both physical and mental) treatment performed by 
professionals; [27] 
• Medicine is a field of science which investigates the ways of diagnosis, disease 
treatment and prognosis. It is a subfield of the healthcare; [28] 
• Telemedicine is a way of providing remote healthcare services by the use of 
telecommunications and IT. Of course, some smart solutions could be a part of 
the telemedicine stack, however healthcare devices are not classified as 
telemedicine tools; [29] 
• Health technology (healthtech) – is a field of technology, where digitalization of 
any type is used to improve the healthcare. Medical technology (medtech) – is a 
subfield of the health technology, which unites all the digital appliances (both 
software and hardware) used in medicine; 
• Healthcare devices are the devices of any type or application, used for healthcare 
needs. With the emergence of information and computing technologies in 
healthcare and rapid development of different systems and products, important 
contrast between professional and consumer appliances has disappeared, however 
healthcare devices could be classified the following way: 
o Medical devices are the ones created for some specific clinical purpose, 
with a focus on a certain condition or a group of them and a long 
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operability cycle. All of the professional machines used by physicians are 
categorized as medical devices. Moreover, any wearable or implantable 
solution, which adjusts human body, senses its biosignals for the analysis 
and diagnostics and interacts with it mechanically is also a medical device. 
Such devices should follow strong governmental and international 
regulations and standards, pass the clinical tests. Examples of medical 
devices are: ECG machinery, MRI scanner, CGM with the insulin injector, 
Apple Watch 4 with its ECG analysis (FDA class 2 device), pacemaker, 
angioplasty catheter; [30] [31] 
o Consumer healthcare products are the ones used to improve the wellbeing 
of users, providing some health data without any analytics or actuation. 
The majority of the existing wearables are consumer products, which do 
not need to follow any regulations or clinical tests. For example, Apple 
Watch 3, Xiaomi Mi Band, pedometer and any type of the pulsometer 
embedded to smart watches are the consumer healthcare products. [32] 
The presented overview of the difference between healthcare devices define the proper 
segment for evaluation, as strategies, prognosis and existing numbers are notably 
distinctive, as well as the market drivers. Consumer healthcare products are developed 
under the pressure of trends and fashion, while the medical devices are aimed to satisfy 
some clinical need. From the other hand, the innovative vision here is that personal 
healthcare approach should incorporate medical devices into daily user’s and patient’s 
routine, so making the medical devices consumer oriented. Exactly this idea explains why 
the versatile market research should be conducted, as the cardiology device makers will 
need to compete with the existing giants, who are already offering both medical devices 
and consumer products with a vision to a medical transformation and a global medicine 
simplification by the use of digital technologies. 
Global market research 
The prototypes of the modern wearable healthcare gadgets were Finnish Polar heart rate 
monitors, released in 1977 for the national sports team. [33] In 1981, the same company 
created a watch with a cardiometer. [34] Until 1995, such devices were non-autonomous 
and worked only with a computer. The prototype of the more modern wearable gadgets 
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was the Nike wristband, created in 2013. It was able to independently monitor physical 
activity and send data to a computer using Bluetooth 4.0. [33] The same year, the Jawbone 
UP24 was released - a smart bracelet that followed the phases of sleep. [35] These 
examples show that the market is quite young.  
According to MedTech, the overall medical technology market size in 2018 in Europe 
was EUR 110 billion, what is approximately stands for 29% of the global share comparing 
to the biggest United States market with its 43% of the global share. [36] Both the 
stationary and end-user solutions were evaluated to form a general statistic. Figure 4 
depicts the regional shares of medical device market globally, while Figure 5 shows the 
European shares by countries. If we analyze the existing market tendency in medical 
devices, a clear growth could be noticed for the last ten years with an average 4,5% annual 
increase. The only exceptive year was 2009, when the international economics crisis 
affected the industry dramatically, however the stable rates were caught up within two 
years, what is illustrated on Figure 6. [37] 
 
FIGURE 4.  Medtech appliances regional market shares in %, 2016-2018.  
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FIGURE 5.  Medtech appliances market shares in Europe by countries in %, 2016-
2018. 
 
 
FIGURE 6.  European medical device market growth rates in %, 2008-2020.  
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As mentioned, MedTech research covers a wide range of medical device applications 
areas – it is interesting that cardiological appliances are among the leaders in terms of the 
share and sales growth. Figure 7 shows an infographic where cardiology is compared to 
other segments. [38] 
 
FIGURE 7.  Global medtech sales and market share in % by segment, 2016-2020.  
If we take a look on all healthcare wearables separately (both medical and consumer 
products) in March 2018, Juniper Research's digital market experts published a report, 
according to which the wearable device market in two years will grow from EUR 200 
million in 2018 to EUR 310 million in 2020. The examples used in the report are the 
AliveCor cardiac devices, and the Quell anesthetic gadget. By 2020, the capitalization of 
these two companies will reach EUR 2.2 billion. As mentioned in the report, the major 
revenue will be concentrated in companies that produce highly specialized gadgets, in 
particular cardio-meters. Even though advanced medical devices are emerging, same 
experts predict a dramatic growth of fitness trackers sales in Asia and a stable tendency 
in the Western part of the world – 75% of the end-user healthcare wearables in China will 
be after consumer products, comparing to 40% and 50% in USA and Europe accordingly, 
what means that the share of personal medical devices in Europe will be a half out of the 
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all offered healthcare wearables, what is a positively big number in terms of this study. 
[39] 
IT enterprises, who have indisputable expertise in the field, are already offering new 
solutions and lead the medical technology market. Apple is a wearable device and medical 
research assistance expert, IBM works on image recognition and physician assistants, 
Google’s area is the accumulation and analysis of data to support medical decisions, while 
Microsoft has a lot of experience in voice recognition and cloud computing to be used as 
infrastructure core. All of the mentioned companies are actively researching AI (artificial 
intelligence) perspectives in medtech. By 2021, the market volume of AI in medicine will 
grow by 40%. [40] However, one of the problems with AI is connected to the data 
markup. If we are talking about the recognition by neural networks of pictures with usual 
objects, this process takes a huge amount of time and resources, but in fact is very simple 
- pictures are mapped to the objects and it could be done basically by everyone, then the 
machine learns. With the medical data it is becoming more and more complicated, only 
specialists can mark it, and the data itself is much more difficult. To simplify, for a day, 
for example, it turns out only in a few MRI processed instead of the required thousands, 
moreover, this final data is very expensive, consequently it turns in a conclusion that the 
competitive advantage of new and smaller businesses in that area is questionable and the 
initial investments should be big. [41] It means that simpler and more specific medical 
data acquisition and its analysis systems are the suitable focus domain for the health 
technology startups and organizations who are new to this market globally. Cardiology is 
a good example of such area domain. 
Another important issue for evaluation is the research and development (R&D) spending, 
as it straightly reflects the market players interest in the segment’s growth. According to 
Statista business intelligence portal research, starting from 2009, the R&D cumulative 
spending in medical technologies is increasing by approximately EUR 1 billion annually, 
hitting EUR 25 billion in 2018. Figure 8 depicts the R&D spending as a percentage of the 
medical technology market revenue. It is clearly seen that the rates stay the same from 
year to year regardless the actual notable revenue growth. [42] 
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FIGURE 8.  Global medical technology research and development costs as a 
percentage of the total market revenue, 2017.  
Health technology industry market in Finland 
According to the research performed in 2015 by HealthSPA ry, the major challenges 
young health technology businesses faced were connected to marketing, trading channels 
and investments. At the same report, it is highlighted that all the respondents and 
healthcare experts believed that "Finland is an excellent platform for companies of the 
sector”, but the development potential of the inner industry communication and its 
problems is also present. [43] This chapter represents an overview of the actual health 
technology market in Finland with the regard to the abovementioned aspects, as they have 
been considered as the most critical barriers recently. The evaluation of the possible 
competitors and partners in the cardiological domain on the local market would be 
performed also. The main focus of the presented study is shifted towards young small and 
middle size organizations, because it implies from the aims of the study. 
Finland is the third (after Denmark and Sweden, which are the Northern European 
countries, so it is also relevant to take them into consideration in terms of this study) in 
the digital economy development in the EU [44]  and is one of the countries with the 
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strongest health technology development in the world [45]. Finland’s health technology 
exports were EUR 2.22 billion in 2017 [46], comparing to EUR 2.11 billion in 2016 [47]. 
If we investigate the annual or the last decade, the exports annual increase is fluctuating 
from 4.3% to 9.7% over every previous year [46]. As health technology is one of the 
leading export segments the organizations in that market are highly supported by 
government and private investors [45], what is especially visible on the VC (venture 
capital) funding. For example, according to the Finnish Venture Capital Association, only 
in the first half of 2018, the overall investment into Finnish companies set a new record 
comparing to the whole previous year, while health technology organizations are the ones 
of the main interest among the investors [48]. 
Existing Finnish health technology organizations (startups) are different and further their 
image is presented based on the following parameters analysis: 
1. Company geographical location – this attribute will allow us to understand where 
the experts of the field are centralized building a connected ecosystem; 
2. Current R&D state – this attribute will allow us to investigate the maturity of the 
market players. Also, the average initial R&D cycle is analyzed in order to 
evaluate how much time does it take to enter the market after the business 
establishment. Of course, products are different, yet this measure reflects the 
general number in the present environment with its market peculiarities;  
3. Funding – the amounts of investments and their source are evaluated to draw a 
conclusion on the average possible third-party financial contribution. 
Furthermore, the business and product development stage correlation to the 
successful investment probability and its amount is analyzed; 
4. Products diversity; 
5. Distribution channels; 
6. Target final user. 
The majority of the Finnish health technology startups were founded after 2012, what 
means that they are present on market for the average of 2-7 years. Almost half of the 
existing companies managed to release their product and entered the growth period by 
2017, at the same time 20% of the organizations did not have any sales at all and 32% out 
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of all companies are entering the market right now. Figure 9 visualizes current status of 
Finnish health technology startups. [47] 
 
 
FIGURE 9.  Finnish health technology startups by product development stages, 
2017. 
Based on the Figure 10, which depicts the geographical spread of the Finland’s health 
technology startups, it is easily seen that the majority of them are headquartered in the 
capital area of the country, what is understandable, as both business and academic 
ecosystems are centralized there. If we take a look on Southwest Finland, only 8% of the 
organizations are settled here, however this region is well prepared for the new medical-
oriented organizations with its fast-growing academic and hospital infrastructure, which 
could be used as a base to start a new business. [47] 
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FIGURE 10.  Finnish health technology startups by region, 2017. 
Medical technology is estimated to be an area with the highest public investment potential 
[49], but the overwhelming majority of the Finnish startups marked funding issues as the 
number one problem in 2017 [47]. From Figure 11, which shows the amounts of 
investments received from the public and private sources in Finland, and from Figure 12, 
where the funds are mapped to the product development state, the following could be 
concluded: 
1. Public investments rarely exceed EUR 500000; 
2. Private finding is less popular among health technology startups, but the amounts 
could be considerably larger comparing to public sources; 
3. Organizations who are starting their R&D are better supported with smaller (up 
to EUR 100000) investments from public sources; 
4. There is a minor tendency in growing companies to receive more funding in 
Finland. 
If we closely consider the fact that Finnish government easily supports startups on their 
early phases, the justification for it could be the scientific research background conducted 
by these organizations. According to the Upgraded study, almost 70% of health 
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technology startups in Finland conducted a preliminary year research [47]. There is no 
available evaluation of its direct impact on funding, however government may consider 
the organizations connected to universities and institutes as more beneficial in terms of 
the final product adoption on national levels. 
 
 
FIGURE 11.  Finnish health technology startups investments in EUR from private 
and public resources by the amount of organizations, 2017. 
 
 
 
 
44 
 
FIGURE 12.  Finnish health technology startups investments in EUR from any 
sources by the amount of organizations and their product development state, 2017. 
As already described, healthcare technology could be consumer oriented, so it will lack 
all the medical aspects. In Finland 47% of startups are working on “wellness” products, 
what means that they have another business and distribution models, comparing to the 
ones interesting in terms of this study. Even if we take a look on the final product nature 
in the all types of organizations (both medical and consumer products), it is seen that in 
2017 only few companies have been working on devices and their system. The majority 
of organizations are focusing on mobile applications (mainly consumer products with no 
medical component) and software. It means that the suggested in the study CAD device 
would be different from the other local products, consequently its investment potential on 
the national levels could be higher in addition to the better social affect justification in 
terms of governmental needs. See Figure 14 for the products nature breakdown. 
To conclude the Finnish health technology startup image overview, Figure 13 shows the 
distribution channels and the final product users of the existing companies. The following 
could be concluded on this: 
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1. The majority of the existing products are targeted to individual consumers. In 
contrast, the CAD appliance would be targeted both to personal use and the 
medical professionals, as the platform have to be connected, what opens a bit 
wider distribution capability – it could be offered both as a consumer product with 
a service and as a platform distributed via public and private healthcare providers; 
2. The process of distribution via public and private healthcare providers is already 
widely used by Finnish health technology organizations. 
 
 
FIGURE 13.  Finland’s health technology startups by distribution channel and end 
user, 2017. 
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FIGURE 14.  Finnish health technology startups by product type, 2017. 
Health technology trade opportunities in Finland and operations region 
expansion 
In according to the shown potential of the cardiovascular smart devices, both in the 
business and social aspects locally, it is relevant to investigate the possible target market 
expansion apart from Finland. Once again, Finnish region shows a good business 
perspective here, because of the tight geographical and commercial proximity with 
Northern Europe (Nordic region) and Russian Federation.  
Nordic countries are actively collaborating in the healthcare sector. For example, Nordic 
Welfare Solutions project was launched in 2017 to promote and export Nordic medical 
technologies globally. Such initiatives are unique especially for that region and encourage 
local organizations to collaborate in the sector. It means that cooperation with neighboring 
companies in the same area could dramatically improve the global market access. 
According to Strongholds and Qualities of the Nordic Health Tech Ecosystem report [50], 
Nordic’s market is highly attractive for personal health technology products piloting and 
commercialization because of the existing trust to public and private organizations from 
citizens, highly developed medical ecosystem and digitalization levels. In addition to that 
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all the Nordic countries have very minor economic differences and entrepreneurship 
targeted to social sector is highly supported by public organizations. 
Alongside Nordic region, according to the Finnish-Russian Chamber of Commerce 
(FRCC) senior advisor, Alexei Kozlov, Finnish companies possess significant market 
opportunities in the Russian medical device market, which is the major segment in 
Eastern Europe. [51] 
Nowadays, Russian medical technology market is estimated to be approximately EUR 
3.5 billion, showing a clear growth, as since 2016 it has enlarged by 10%. [51] [52] A 
very important factor in terms of this study is the fact that the Russian medical devices 
market is highly dependable on import, which is 80% out of the total value [52], while 
Finnish technological products are highly reputable by consumers and governmental 
customers in this region, especially in the core capital subjects of the country. Of course, 
medical devices are very versatile, and the needs of the Russian healthcare system are not 
centered in cardiological appliances, however almost quarter, 22%, of the market is taken 
by diagnostics and disease prevention. [51] Moreover, because of the national project 
“Health”, with its major aim to revive the preventive healthcare by providing the 
population with hightech medical solutions, the popularity and need of the personal 
medical devices will increase, specifically in cardiology, as CAD, which is the target 
disease of this study, is responsible for 28.9% of lethal cases in Russia. [53] 
Unfortunately, the existing regulations for the medical devices in Russia are quite 
indefinable, what has been recently addressed by the government. Currently, the Eurasian 
Economic Union (EEU) members are actively working on the centralized standardization 
for medical technology solutions, what should result in a common market by 2021. [54] 
[55] In practice, it will allow the business of interest of this research to enter the bigger 
market (5 countries) promptly with clear certification process, what means that Russian 
market of medical devices is worth to be accessed also from that point of view. 
Market of CAD and other cardiovascular digital solutions  
This section shows and discusses the existing innovative products for CAD detection 
available globally. Moreover, the most interesting possible partners are evaluated among 
local companies. 
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As Finnish market currently lacks any cardiovascular disease diagnosis and monitoring 
medical devices (Polar, Suunto, Bittium, VitalSignum (Beat2Phone) and Nokia products 
are not counted in this study as they offer only “wellness” or stationary products), the 
evaluation of market players was narrowed specifically to CAD and audio cardiography 
(see section CHAPTER 4: CAD diagnostic system functional specification and design for 
more details) solutions. Following devices exist (at the state of April 7, 2019): 
1. AUM Cardiovascular CADence system (USA, Minnesota); [56] 
2. Acarix CADScor (Denmark). [57] 
AUM Cardiovascular CADence system is a novel method of coronary artery obstruction, 
heart failure and valves abnormalities diagnosis via examination of the heart sounds and 
ECG. Developers claim that product is targeted for the clinicians’ usage to perform the 
required diagnostic during the triage process, what means that it is a professional medical 
gadget not available for consumers straightly. In addition to a handheld device (sensing 
unit), infrastructure includes the following: 
• Patient’s recordings journal; 
• User application; 
• Computing system, which is used to analyze the collected data. 
If we evaluate the whole system, it is breakthrough appliance to be used in hospitals by 
professionals, however it lacks any personal approach fraction or platform vision, what 
means that it could not be used widely in a connected manner. Patient’s data is not 
aggregated anyhow or stored. No possible further extensions in terms of the device 
applications are publicly available. The sensing unit itself is quite cumbersome and 
inapplicable for wearable applications. On the other hand, AUM Cardiovascular 
CADence system is a perfect reference and possible strong market competitor. The 
product was already widely tested, and it is appeared that audial detection of turbulence 
in the blood flow, caused by the plaques in artery is a progressive but still difficult and 
unclear method [58]. 
Taking into consideration Acarix CADScor system, it is obvious that it is a more 
advanced version of the previous example, which is also targeted for professionals. 
According to developers, the device was already proven on clinical tests and showed 
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perfect results – the negative predictive value is 93-97% [57]. It is important to mention 
that Acarix company is based in Denmark, what makes the selection of the same product 
applications and target group impractical. Luckily, the suggested solution in this study is 
different by nature and business model, even taking into account that same technology is 
used. In addition to a close Acarix location on the market map, the company is actively 
selling the solution. According to their report from 2018, 22 devices and around 2000 
patches were purchased, what is twice bigger amounts comparing to 2017. Finally, Acarix 
started to research other possible applications to enlarge the use scope in hospitals of the 
CADScor system, for example, investigation on possible diagnosis of heart failure started 
in 2019. [59] 
Both of the overviewed devices are not prototypes and are available on market, however 
there is no publicly available information about pricing, certifications, as well as there is 
no user’s feedback, what is of course understandable because of their distribution model 
nature. None of the devices is available for consumers and none of the systems provide 
any kind of platform for patients and medical data aggregation, what means that Acarix 
CADScor and AUM Cardiovascular CADence are very innovative professional tools. 
Unfortunately, none of them incorporate monitoring and diagnostic into the normal 
lifestyle, what does not lead to innovation in the medicine paradigms. Patients still need 
to visit the doctor and perform the examination. All of the abovementioned facts make 
the proposed in the document solution valid and competitive. 
Exploration of other cardiovascular innovative gadgets depicted that there are a lot of 
ECG solutions with versatile focus conditions. Mainly, atrial fibrillation and basic heart 
rate control are targeted. Such solutions utilize the same idea of providing medical 
monitoring and analysis directly to consumers. At the same time, some startups are 
working on platforms separately to aggregate the collected data building a patient’s 
profile. The last-mentioned companies should be considered as possible market partners, 
as they already have the infrastructure to deliver solution as a service. For example, 
Finnish RemoteA offers an ECG analyzing platform, which not only performs the 
automated data analytics, while it connects the patient with his or her attending physician. 
Considering the development of the CAD appliance, mobile application and sensing units 
set, it could be used as the data collection element, while RemoteA could extend the 
platform to build a ubiquitous service for cardiovascular diseases assessment. In addition 
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to such partnership, collaboration with Acarix could be interesting, as it will offer an 
ability to transfer the working ecosystem to the new auditory changing the way of doing 
business. Such perspectives are presented only for reference, however, in order to 
evaluate them Acarix CEO, Per Persson, and CMO, Dr. Anja Schaefer, were interviewed. 
Also, this session helped to investigate experienced professionals’ vision to audial 
detection in cardiology. Interview questions and answers are attached in Appendix 1. 
Following conclusions could be made out of it: 
1. Disease diagnostics in the patient’s side is risky, because patients do not have 
enough competence to evaluate them. This statement is clear, and it means that 
any personalized medical device should not make the final diagnosis. Such system 
should provide recommendations, knowledge, tracking and estimations that there 
is a possibility of the presence or absence of the target condition. Final decision 
making should be done and, what is more important, delivered to patient by an 
experienced medical specialist, connected to the service infrastructure of the 
appliance. To summarize, this aspect is critical, and it would be taken into account 
in CHAPTER 4: CAD diagnostic system functional specification and design; 
2. According to Acarix experts, patients’ skepticism is not about technologies in 
cardiology only, it is more about trust to the whole medical system; 
3. Because of the early stage development, Acarix is focusing on own model and not 
very actively looking for partners. 
Market study conclusions 
Based on the conducted study, the following generalizing conclusions could be made: 
1. There is a positive tendency in Finnish health technology market, it is well-
supported by government and private investors; 
2. Finnish public healthcare segment is difficult to enter, what means that product 
distribution also should be an end-user oriented, what implies from personal 
healthcare and is considered in the CAD appliance; 
3. Early diagnosis and preventative solutions are harder adoptable in public sector, 
as they do not provide a rapid impact on the society. In turn, long-term 
investments are less attractive for government and some private organizations, 
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what is a drawback in terms of CAD product, however the vision on the platform 
expansion could be interesting for investors on national levels; 
4. Scientific research background in the area is an advantage in terms of the 
successful funding in Finland; 
5. Currently there are no competitors on local market in terms of the CAD appliance. 
Similar medical devices are available; however, they are not applicable for 
personal healthcare. The strongest possible competitor is located in the region of 
Northern Europe; 
6. Marketing and product adoption could be difficult in the health technology sector 
in Finland; 
7. Finnish market is small and business expansion should be considered during the 
first phases. Nordic countries and Russia are the most accessible and interesting 
areas. As for the local market, metropolitan region is the optimal settlement area 
for a new medical technology business, however, Southwest Finland and 
Pirkanmaa regions are actively developing. As for the Southwest Finland 
specifically, it offers a wide range of possibilities because of the large amount of 
medical and other healthcare institutions, as well as private companies; 
8. Based on the fact that CAD is occurring in adults and elders in Finland (see section 
CVD in Finland for more details) and the idea of consumer orientation of new 
smart medical products, adults is the optimal target user group for the first several  
stages at least. Selecting elders as the primary focus group could result in 
problematic and long product design, as digital literacy and capabilities among 
this age group are underdeveloped. Moreover, marketing tools are different, while 
in accordance to issue 2 of this list, product promotion via public healthcare 
providers is questionable; 
9. Final solution should be a platform for CAD and cardiovascular diseases 
management without a straight diagnosis capability. Common people are not 
ready to analyze the medical results and prepare the treatment plan. It means that 
platform should provide tools for data collection, communication with service 
providers and pre-diagnostic predictions of possible condition presence.  
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Distribution channels 
Even considering the fact that collaboration with Finnish public healthcare organizations 
could be complicated, that distribution and marketing channel should be considered as 
the primary one with a remark of including any other healthcare organizations and service 
providers. 
The above-mentioned fact is coming from the idea that only direct-to-consumer 
distribution model is risky for medical technologies companies because people do not 
trust themselves to diagnose a serious condition, what coronary artery disease is. This 
discussion is also related to the core difference between medical and wellness products, 
as well as to the Acarix specialists’ interview answers. According to Lisa Suennen, Senior 
Managing Director at GE Ventures, consumers are not willing to straightly pay for 
medical devices because there is a well-established opinion that government and 
insurance companies are responsible for it. [60] 
The logical conclusion out of it is not the whole model change need, as the device still 
require to be consumer-oriented, while is that correct impact on those who impact 
customers should be conducted. It means that marketing should be performed via 
specialists’ integration because doctor’s expertise is everything for the patient. In 
addition, final solution should incorporate professional mode, which will allow the 
stationary system use, what in turn affects the appliance adoption in professional society.  
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CHAPTER 4: CAD diagnostic system functional specification and 
design 
This section represents an overview of the designed digital system for coronary artery 
disease detection and monitoring – its functions, ways of data collection and analysis. 
The suggested solution is called Lub.dapp and currently consists of the following 
modules: 
1. Phonography device; 
2. 1-lead ECG acquisition device; 
3. iOS application; 
4. WatchOS application; 
5. Cloud platform for data analysis (backend infrastructure, API, data analysis 
algorithm implementation); 
6. Web-based interface for healthcare providers. 
The following is included to the scope of the practical work of this study, alongside the 
market research presented in the section CHAPTER 3: Medical digital technologies 
market research: 
1. Functional specification of the suggested system; 
2. Phonography device model; 
3. 1-lead ECG acquisition device model; 
4. iOS mobile application interface architecture; 
5. WatchOS interface architecture. 
Solution overview and functions 
Lub.dapp is an appliance targeted both to consumer and professional use. Currently, only 
consumer-oriented design and functions are assessed. The main idea underneath 
Lub.dapp is the vision to create a platform for cardiovascular system management in 
patients and persons who are interested in healthy lifestyle. Following core functions are 
included into the current version of the product: 
1. Thematical newsfeed; 
2. Measurements; 
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3. Heart ID; 
4. Guest profiles and Doctor’s profile. 
Thematical newsfeed (application screens with the newsfeed and a post are depicted in 
the Figure 15) is included into the application and following characteristics apply to it: 
• Basic medical knowledge is an important aspect for correct disease management. 
As heart conditions are very interconnected and mainly occur because of the same 
causes, users should learn more about their organisms. Educational component 
provides that functionality in a simple and common format; 
 
         
FIGURE 15.  Lub.dapp home screen with the thematical news feed (left) and the 
post screens (middle and right). 
 
• If the user is not a consumer and a professional’s account is configured, basic 
posts are excluded, while different research overviews, novel technologies in 
cardiology reviews and practices are provided. By idea, any medical specialist 
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may become Lub.dapp’s partner and deliver valuable content for the community 
of cardiologists. This feature is not yet implemented in the developed mock-up; 
• Of course, the presence of such materials requires a solid publishing department 
what could be problematic at the first phase, however this feature makes Lub.dapp 
different from other market players, as no one focuses on both educational and 
functional services. 
Measurements component provides the possibility to control heart vitals and create the 
patient’s Heart ID with detailed statistics, CAD and atrial fibrillation diagnostic 
predictions. Of course, phonography device, so-called Lub.audio, is the main distinctive 
part of Lub.dapp, however single CAD detection is questionable in terms of proper 
product placement. Consumers are looking for complex and interesting solutions. CAD 
detection itself is not a daily activity in terms of non-professional use, consequently the 
system includes the following wider data measurement and recording possibilities 
altogether: 
• Audial CAD detection – Lub.audio phonography device is used to capture heart 
murmurs. Device itself is a wearable unit, which consists on the following 
elements: 
o Standalone detachable silicone patch, which is glued to the human’s chest 
and used as an interface for the microphone. Medical silicone allows users 
to take a shower with the patch attached, while special perforated structure 
and glue verify strong connection and proper airing. Lub.audio is screwed 
into the patch and is secured by a clip. Lub.audio and patch renders are 
shown in the Figure 16; 
o Sensing membrane, which tightly touches the chest surface, provides the 
impedance matching interface for the microphone unit. See Figure 17, 
where Lub.audio is shown from the back and the membrane is visible; 
o Microphone unit with a sensitive cardiological sound recording sensor. 
The selection of the exact electronic component is out of the scope of this 
study, however such components are widely available on market, as they 
are used in the digital stethoscopes; 
o Processing unit, which is used for initial signal conversion and processing; 
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o Bluetooth communication module, which is used to transfer the data from 
the wearable device to the smartphone for data collection and transport to 
the cloud system in order to perform the analysis; 
o Wireless charging (QI) and battery components; 
o Switch to control the device operations; 
o 2 LEDs to provide feedback for the user; 
Lub.audio is made of soft-touch plastic and has the following dimensions 
(diameter/thickness) – 40mm/15mm. It is designed to be a waterproofed device, 
meeting the IEC 60529 IP68 requirements [61]. 
• 1-lead electrocardiography (ECG) Apple Watch band, so-called Lub.band, is used 
to capture ECG signal. The main purpose of it is to collect timing data for audial 
CAD detection. Secondly, Lub.band could be used to take ECG measurements for 
arrhythmia (atrial fibrillation specifically) detection. In the future, ECG module 
with the pulsometer could be manufactured as a standalone device. Currently 
Apple Watch is used to complement the infrastructure, while if Android device is 
used, some Android smart watches’ or a separate silicone bands could be used to 
hold the sensors. From the electronics perspective, 1-lead ECG module 
incorporates only a sensor (exact component is not selected but they are available 
on market) and a Bluetooth chip to transfer the data and control the unit. Lub.band 
is depicted in Figure 18; 
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FIGURE 16.  Lub.audio front view and human body connection patch. 
 
 
FIGURE 17.  Lub.audio back view. 
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FIGURE 18.  Lub.band attached to Apple Watch Series 2. 
• Blood pressure (BP) measurements could be added manually into the application 
in order to add a critical layer of information to complement ECG and audio data. 
Currently, Lub.dapp lacks any BP measurement device, however this 
development should be considered in the future. Withings Wireless Blood 
Pressure Monitor [62] is a nice example of such solution, moreover, that device 
could be considered as an integrated unit, as Withings provide a public API; [63] 
• Heart rate (bpm), energy consumption (kcal) and exercises (minutes) data is taken 
from Apple Health application to outline all the important information for 
cardiovascular system at the same place. The data collection is performed via 
integration to Apple HealthKit, while physically the signal is collected by Apple 
Watch. [64] 
All of the measurements are used to build the daily statistics. If the user is not performing 
them often enough or some abnormal activity (increased or decreased heart rate) is 
detected, the application reminds the user via push notifications. ECG, phonography, 
heart rate and BP data are collected and shown on the special application sections, where 
analysis, graphs and diagnostic results are depicted. Graphs are designed to be developed 
via native iOS and Android visualization libraries to provide interactivity, smooth 
zooming, scrolling and dynamic segmentation changing. See Figure 19 for BP and 
phonography data visualization in the application. 
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FIGURE 19.  Lub.dapp BP data section screen with the graph (left) and the 
corresponding phonography data screen (right). 
Measurements data is complimented with the user’s Heart ID, where his or her main 
health information is configured. When the user attempts to export the measurements 
data, the Heart ID is automatically included in the report. Data is exported in the form of 
the PDF file, which could be sent to the healthcare provider’s email. In the future, 
healthcare provider’s web-based interface is planned, while public sector adoption may 
be more difficult because of it, as every new system integration into the usual flow is a 
task of notable complexity. Fields of the Heart ID, which are added by the user, are shown 
in the Figure 20. 
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FIGURE 20.  Heart ID screen. 
Lub.dapp is targeted to adults and as constant monitoring is not required by the nature of 
CAD, which is the major condition in the system, guest profiles are incorporated into the 
application. Such an approach allows the main user to create simplified separate guest 
Heart IDs and record measurements to it.  
Guest profiles are mainly targeted to the family use. As the device price is not low, some 
people may not afford a set of them for each member of the family. Patches could be 
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shipped separately, what will give the possibility to offer the whole appliance to bigger 
target auditory with different income. From the business perspective it is profitable, as 
more devices could be purchased, while the development and support costs are minimal 
for guest profiles. 
Professional mode of the application implies the absence of the Heart ID at the core of 
the account, while doctor creates his professional profile and Patient IDs inside of it. 
Patient ID and doctor’s mode are not yet designed, while the following peculiarities are 
planned: 
• Additional data would be added to the Patient ID, comparing to Heart ID, as 
cardiologist need to keep track of all the tests at one place. The exact set of new 
parameters is not yet defined; 
• Performed measurements would provide more detailed diagnosis reports, while 
consumers will get the recommendations only in order to avoid false positive 
results and corresponding users’ reaction: 
o For CAD and AF detection, consumer will receive one of the following 
results: 
§ No signs of CAD (or AF) detected; 
§ Possible signs of CAD (AF) were detected; cardiologist visit is 
recommended; 
§ Not enough data for analysis; 
• Cardiologist-to-Patient communication ability should be added in order to provide 
a platform for medical service. Possibly, a chat, appointment booking system and 
calendar would be added on further phases. 
Data collection and analysis 
Recently, a rapid development of electronics and data modelling and analysis methods 
dramatically expanded the applications of acoustic cardiography, so-called 
phonocardiography (PCG). This method provides notable benefits for patients, as it is 
completely non-invasive, save and convenient to use, because human body is not affected 
in any way. Moreover, even the most advanced and accurate audio sensors for medical 
applications are quite cheap in manufacturing and have long operation period. All these 
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benefits open a possibility to transfer PCG to the personal healthcare, both for diagnostic 
and monitoring usage. 
In case of CAD diagnosis, PCG is a natural method, as atherosclerotic lesion of the 
coronary artery changes the normal laminar blood flow and creates flow turbulence at the 
point of the coronary stenosis. In turn, additional flow friction occurs and releases audio 
mechanical signals. [65] Characteristics and patterns of this acoustic waves generated by 
the turbulenced blood flow could be analyzed and compared to acoustic waves of the 
normal blood flow for the diagnostic purposes. Such devices already exist and they are 
outlined in the Market of cardiovascular detection and monitoring solutions section, 
however none of the solutions is targeted for the end customer, in contrast they are aimed 
for the in-stationary usage by physicians only.  
The trend of PCG usage for CAD is not new and some other fundamentally different from 
blood flow sound analysis techniques were investigated. For example, in 2009, a group 
of researchers from University of California investigated the changes over the third and 
fourth heart tones caused by atherosclerotic lesion. Unfortunately, the model did not 
provide a production ready method because of the poor accuracy and specificity. [66] 
CAD turbulent blood flow audial detection 
The first challenging issue in terms of data collection is the nature of the coronary arteries 
– they are small and moving. Moreover, they are located notably far from the body 
surface. All these factors dramatically complicate the process of the audio signal 
acquisition. In addition to that, the turbulence sounds are tiny and highly-dependable on 
different factors: the turbulence of the blood flow enlarges simultaneously with the 
increasing blood flow rate up to some threshold and is changing because of the blood 
viscosity and vessel channel size. Of course, in case of major atherosclerotic lesion in the 
vessel, the turbulence could be detected at the normal blood flow rates, however in more 
primary CAD development stage increased blood flow rates are beneficial for the 
detection, what impacts the conditions when measurements should be performed. 
Existing physical characteristics of sounds associated with CAD are blurred. According 
to [67], CAD blood flow turbulence is audible at 10-800 Hz, what is overlapping with the 
valve sounds and heart murmurs located at 10-400 Hz. Current device makers are 
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targeting different frequencies in their solutions, however frequency spectra around 100-
600 Hz is the optimal one in terms of the personal wearable device, as it is easier to tackle 
and filter. It was also shown by analyzing patients before and after stenting surgery that 
CAD audio signatures above 300 Hz are more common. [68] [69] [70] [71] 
As seen, turbulence sounds frequency is overlapping with another heart sounds, 
consequently some timing characteristics should be considered in order to target the 
needed frequency in the absence of irrelevant noise. The most suitable period for the 
target sound detection is the diastole, as at that time there are no additional noise coming 
from the heart contraction. According to [72], the sounds of the corrupted blood flow in 
the coronary tree are mostly audible with a delay of approximately 250 ms after the 
second heart sound. Luckily, exactly this period is associated with the most powerful 
coronary blood flow, so the sounds of interest would be the loudest. In order to have 
additional data about heart cycles and their timings, simple 1-lead ECG is used together 
with the audio cardiography appliance. First of all, it will allow to easily isolate the needed 
time period, eliminating the noise from the valves’ operation. In addition to that, 
integration of 1-lead ECG to the system will make it more scalable and flexible in the 
future, what means that not only CAD and atrial fibrillation could be analyzed. 
Recording module, its placement and measurement cases 
Based on the nature evaluation of the sounds associated with CAD, the recording module 
is the following – a sensitive cardiac microphone (in cardiology, so-called electronic 
stethoscope), which delivers the signal for a basic amplification, pre-processing and 
analog-to-digital conversion module, from where it is transferred via Bluetooth  to an iOS 
smartphone.  
Lub.audio is small as it is attached to the human’s chest. It is also light-weight, as signal-
to-noise ratio should be very high with a capability of operations at high frequencies 
(above 500 Hz), where external noise caused by a physical object movement due to the 
appliance placement is extremely disturbing. The most suitable microphone design for 
audio cardiography is the impedance matching one, what means that special interface (for 
example, fluid, gel or foam) is used to match the impedance between the body surface 
and the sensor. As mentioned previously, Lub.audio membrane provides the impedance 
matching capability.  
 
 
 
64 
Such cardiological microphones are commercially available and used for different 
medical applications already. However, even the presence of the needed audio sensors 
does not solve the complexity of the proper measurements fully. Regardless the 
microphone accuracy and filtering algorithm capabilities, the recording should be 
conducted in silent setting, what has its impact on the device applicable use cases. 
Luckily, CAD does not require permanent monitoring as randomly occurring atrial 
fibrillation, so this usage peculiarity is not affecting the usability and convenience now. 
Phonocardiogram measurement process with the following characteristics is suggested 
for the created device: 
• Total duration of the measurement is 5 minutes; 
• During the measurement the patient should hold the breath 4 times for 15 seconds, 
what will help to eliminate the acoustic interference. All 4 holds will take place 
starting from the second measurement minute. 
Lub.audio should be placed in the apex position of the heart by default, what is also in 
the 4th intercostal space, 5 centimeters to the right of the sternum [73]. Other positions to 
investigate another heart section could be recommended directly by the cardiologist. 
Following cases are recommended at that phase for phonocardiography: 
1. Presence of chest pain and attacks; 
2. Weekly measurement; 
3. Measurement after doing sports; 
4. Measurement while doing training of high intensity; 
5. Measurement in the occurrence of increased BP and heart rate. 
Application design 
iOS application interfaces mock-up (iPhone XS) is attached in Appendix 2. Below is the 
screen by screen functional description (item number in the numbered list corresponds to 
the screen number in Appendix 2): 
1. iPhone home screen with Lub.dapp icon; 
2. Notification list with the following alerts from Lub.dapp: 
a. New educational post added. If clicked, post screen (39 or 40) opens; 
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b. Device battery level is low. The same notification is used for Lub.audio 
and Lub.band. If clicked, application settings screen (70) opens; 
c. Increased heart rate notification, which recommends making a 
phonocardiogram. If clicked, measurement setup screen (78) opens; 
3. Splash screens, which depicts application logo and project name to occupy the 
loading time; 
4. Passcode screen, which opens immediately after the application start if the user is 
authenticated and his or her profile is fully set up. Passcode is used together with 
biometrical scanners (in iPhone Touch ID and Face ID are possible, depending on 
the device version) to secure the private medical data. Passcode configuration is a 
mandatory step of the account creation; 
5. Face ID scanning in process; 
6. Face ID scanning is successfully done. Just after it Today screen (38) opens; 
7. Sign in screen, where user needs to enter the authentication credentials. This 
screen opens after the Splash screen (3) if no active authentication token is 
present. Otherwise, Passcode screen (4) opens; 
8. Sign in screen with the filled in information; 
9. Authentication error; 
10. Password recovery screen, where user enters the used email and the recovery 
message with a deep link is sent. When the deep link is clicked in the mail client, 
the application catches it and opens the screen with new password creation (12); 
11. Confirmation that the recovery link was sent to the mentioned email; 
12. New password creation after the recovery process; 
13. Sign up screen, which is the first screen for account creation; 
14. Email verification screen, which is a part of the account creation process. 
Verification is done using the code, which is sent to an email; 
15. Screen with the data policy and terms of use text and confirmation functionality; 
16. State of the previous screen, showing the agreed policy and an active button; 
17. Passcode creation to be used for application access; 
18. Passcode confirmation to ensure the absence of incorrect clicks on the previous 
screen; 
19. Face ID activation; 
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20. Account creation summary and mode selection. Currently, only consumer’s mode 
is possible. In the further versions, professionals would be able to create doctor’s 
accounts; 
21. Creation of Heart ID screen, where user adds his or her basic medical information, 
which is required for data analysis. Additional information could be configured 
later on via Heart ID screen (85). Following parameters are mandatory: 
a. Name; 
b. Surname; 
c. Date of birth; 
d. Gender; 
e. Weight; 
f. Height; 
g. Blood type; 
h. Existing medical conditions – user should select all conditions in the list 
that apply to him or her. The diseases list is downloaded via API and it 
covers the majority of popular conditions. If some condition is not in the 
list, a manual note about it could be added; 
i. Medications – similar to medical conditions, all medications in the list that 
apply should be selected. Design lacks that exact screen as it is the same 
as the medical conditions selection interface; 
j. Allergies and reactions – this selection component works the same way as 
the previous one; 
k. Activity levels slider, which should be positioned at one of the ten fixed 
points; 
l. Angioplasty (stenting) – user should turn the switch on, if the surgery was 
performed. Angioplasty is highlighted as it is relevant in terms of CAD 
detection; 
22. Medical conditions for Heart ID selection; 
23. Numerical input in Heart ID creation step; 
24. Heart ID configured completely; 
25. Avatar selection. If no profile image is selected, initials are shown on the avatar 
by default; 
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26. Avatar creation method selection. By default, iOS allows to select an existing 
image from the Library or take a new one via Camera application; 
27. Profile picture is configured; 
28. Preloader used to confirm the Heart ID creation and allocate time for data 
synchronization with the backend; 
29. Application’s home screen, so called Today screen. This screen represents the 
case when user has just configured the profile, so the following tiles are shown: 
a. “Allow access to Health application” – by pressing this tile, user allows 
the application to read data via HealthKit, what is needed for heart rate, 
energy and exercises information. As soon as the access is permitted, the 
tile will disappear;  
b. “Connect your band and Lub.audio device” – by pressing this tile user 
connects his or her devices via Bluetooth. Pairing should be done only 
once. If the devices disconnect, the tile appears, otherwise it is shown only 
once; 
c. Two tiles with posts about the project and CAD to outline the core 
concepts and functionality underneath Lub.dapp; 
30. Native iOS data access request for Health application data. When “Settings” 
button is clicked, user is redirected to system settings; 
31. Lub.audio Bluetooth pairing initialization. See screen itself for the connection 
procedure; 
32. iOS native Bluetooth pairing request; 
33. Lub.audio device successful connection confirmation; 
34. Lub.audio device connection error; 
35. Lub.band Bluetooth pairing initialization. See screen itself for the connection 
procedure; 
36. Lub.band device successful connection confirmation. In case of error, refer to 
screen 34; 
37. Preloader; 
38. Home screen after device connection. Comparing to screen 29, only educational 
thematical posts are shown. Following tags (topics) are planned in the consumer 
mode: 
a. “Cardiology” – specific reading about cardiovascular conditions; 
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b. “Heart health” – general health recommendations, reviews, interviews and 
discussions; 
c. “Learn more” – reading about technologies used in Lub.dapp, project and 
similar issues; 
d. “Nutrition” – healthy eating recommendations, recipes, discussion on diets 
and meal planning; 
Any post could have only one tag. Posts are also classified based on the presence 
or absence of the cover image. 
39. Post with a photo; 
40. Post without a photo; 
41. Heart section home screen, which is used to outline daily statistics. Following 
functional components are present on the screen: 
a. Quick date picker used to select the day for investigation. The calendar is 
scrollable, however if the user wants to select a date notably in the past, 
native date picker carousel could be called by pressing the corresponding 
button in the top navigation bar; 
b. Measurements list, where all the performed records are listed in the 
chronological order. If clicked, details will open. If swiped left, the 
measurement could be deleted; 
c. Health app data section, which includes 3 tiles: 
i. Heart rate, clicking on which open the details screen; 
ii. Exercises minutes, clicking on which offers to open the native 
Health application, see screen 45; 
iii. Total energy consumption today, clicking on which offers to open 
the native Health application, see screen 45; 
d. Notes, where users may write some free-format text notes; 
e. Data export button, which initiates the report preparation and export 
process; 
42. Measurement delete confirmation; 
43. Heart section date picker carousel; 
44. Heart section with no data available for the selected date; 
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45. Health application redirect confirmation. See screen 41 description for more 
details; 
46. Heart rate details screen, which includes the following functionality: 
a. Date picker, similar to one described for screen 41; 
b. Graph 
i. Tab switcher is used to select the period for visualization; 
ii. Vertical axis shows the heart rate values, the horizontal axis holds 
the timestamps; 
iii. One box plot on the graph is used to outline the heart rate 
measurements. Red and blue dots are used to represent the 
maximum and minimum recorded values respectively; 
iv. If the box plot or local minimum or maximum are clicked, box with 
information occurs below the graph grid; 
v. The chart is designed to be scrollable and zoomable; 
c. Basic and derived heart rate value parameters list. If the record is clicked, 
the information screen is opened to justify the meaning of the parameter; 
47. Measurement record information screen; 
48. Blood pressure details screen, similar to screen 46. Graph depicts the 
measurement’s systolic and diastolic readings, manually added by the user; 
49. New BP record adding screen; 
50. Numerical input on new BP record adding screen (49); 
51. Data export configuration screen, where user can select the period for exporting, 
include or exclude the parameters to be added into the report, as well as specify 
the destination email address for the report. By default, email used in profile is 
automatically entered; 
52. Export report preparation and sending preloader; 
53. Measure section main screen, which consists on 3 tiles and profile selection: 
a. Tiles with measurements types and their short descriptions: 
i. 1-lead ECG; 
ii. Heart phonocardiogram; 
iii. Blood pressure; 
b. Selected profile is shown in the top navigation bar. By default only one 
profile is created with Heart ID, however as described in Solution 
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overview and functions simplified guest profiles could be created to share 
the appliance; 
54. Error popup, which is shown in case ECG or phonocardiogram could not be 
conducted because of no sensors connected; 
55. Profile selection screen. If the guest profile is swiped left, it could be deleted 
including all the personal data and records. Default profile could not be deleted 
from this list, however it is possible through Settings (screen 78); 
56. Profile removal request confirmation; 
57. Guest Heart ID creation; 
58. Preloader for guest profile creation; 
59. ECG measurement instructions. See screen itself for measurement procedure 
description; 
60. ECG measurement start screen. If user wants to select a guest profile for the 
measurement, it could be done by clicking “Measure for another person”, what 
will open screen 55; 
61. ECG measurement process; 
62. ECD measurement processing preloader; 
63. ECG measurement report, which includes the following: 
a. Measurement timestamp; 
b. Heart rate parameters; 
c. Interactive graph with ECG line; 
d. ECG results; 
e. Free format text note section, where user may specify the symptoms or 
describe the case when the measurement was taken; 
64. ECG measurement report with activated text input field; 
65. ECG measurement report with positive AF and tachycardia result; 
66. Phonocardiogram measurement instructions step 1. See screen itself for 
measurement procedure description; 
67. Phonocardiogram measurement instructions step 2; 
68. Phonocardiogram measurement instructions step 3; 
69. Phonocardiogram measurement instructions step 4; 
70. Phonocardiogram measurement start screen, which is similar to screen 60; 
71. Phonography device tuning preloader screen; 
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72. Phonocardiogram measurement process; 
73. Breath hold popup, which appears to inform the user about the need to alter the 
breathing process. Seconds counter is used to outline the amount of time with no 
breathing; 
74. End of breath hold popup, which informs the user that currently usual breathing 
is required; 
75. Phonocardiogram measurement report, similar to screen 63 in terms of structure 
and functionality; 
76. Phonocardiogram measurement report with positive CAD result; 
77. Phonocardiogram measurement report in case of no analysis is possible; 
78. Application settings, which include the following functionality: 
a. Devices battery levels; 
b. Push notifications configuration; 
c. Email and passcode change functionality; 
d. Profile removal, which deletes all the personal data and records. If user 
deletes the profile, full-time report is prepared and sent automatically, 
supplemented with the Heart ID; 
e. Rate us button, which calls the SKStoreReviewController to open an iOS 
native application review popup; [74] 
f. Support button, which opens an email client with the preconfigured 
destination and topic; 
g. Application version mark; 
79. Passcode reconfiguration step 1; 
80. Passcode reconfiguration step 2; 
81. Passcode reconfiguration confirmation; 
82. Email reconfiguration; 
83. Email reconfiguration confirmation; 
84. Profile removal confirmation; 
85. Heart ID main screen. If the parameter record in the list is swiped left, information 
screen opens, which is similar to screen 47. 
As Apple Watch are used as an additional sensing unit and Lub.band device connection 
appliance, WatchOS application is designed to ease the measurement process. Such an 
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extension is needed to unite the ecosystem. Lub.dapp Watch application mock-up is 
attached in Appendix 3 and has the following functionality: 
1. Authentication via passcode; 
2. Today’s measurements overview; 
3. ECG measurement initiation and control; 
4. Phonocardiogram measurement initiation and control; 
5. Blood pressure record creation. 
Discussions, extensions and other possible applications 
The created design, devices models, market evaluation and compendious functional 
description are, of course, just the initial development stage and the product is far from 
being in the production ready state. The purpose of the conducted practical assessment 
was to illustrate the direction to where the CAD management could grow to as a 
manifestation of the personalized medicine.  
As far as the vision and solution model is clear, the next critical question is the data 
analysis. None of the other mentioned components of the system have so diffused list of 
concerns. It is already clear that audial CAD detection method has compelling and serious 
limitations, both from the physical signal acquisition and data analysis perspectives. 
Blood flow turbulence requires the presence of sufficient occlusions and flow rates to be 
detected. Currently, it is also difficult to answer how big plaques should be formed to 
create the turbulence murmurs, what are the effects of blood viscosity changes and what 
kind of other factors may increase the possibility of proper and accurate CAD diagnosis. 
All of that questions mean that the methodology is not yet completely applicable for early 
phase disease detection. In addition to that, audial detection does not provide the toolset 
for coronary occlusions and turbulence localization. 
All of the abovementioned issues require the collection of big amounts of patients’ data 
with and without CAD, angioplasty and other cardiovascular conditions. Creation of the 
product could lead to the data collection phase, but the market offer should be changed, 
because initially Lub.dapp would not be able to detect CAD. It is the main reason why 
educational component, ECG, BP reading, Heart ID and other additional functionality 
was added into the system. In other words, the presence of wide feature set and modular 
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system would allow to release the first version faster, what will initiate the data collection 
and analysis step to create a proper algorithm for CAD diagnosis.  
As amount of labeled data required is huge, public adoption of the solution is critical, 
what means that professional mode development at early phase is needed, even counting 
the fact that the initial idea is to target consumers and offer personalized medicine service. 
Returning back to Distribution channels, targeting the ones who affect the final customer 
is the correct model. 
To summarize, Lub.dapp is a very promising project from business, medical, social and 
technological perspectives and in order to release the system following steps are required 
nowadays (only major development vectors are listed): 
• Technological aspects 
o Algorithm creation; 
o Lub.band and Lub.audio electronic design and hardware development; 
o Backend development 
§ Application business logic and API; 
§ External facing API to connect partners and share data with public 
and private healthcare providers; 
§ Content delivery network management; 
o Data security and users’ protection; 
o Service provider’s interface; 
o iOS and Android mobile application development; 
• Medicinal aspects 
o Investigation of unknown audial CAD markers; 
o Research of other possible phonocardiography applications 
§ Heart tone analysis; 
§ Air movement through the respiratory tract monitoring system for 
CVD and bronchial patency detection; 
§ Heart failure diagnosis and monitoring; 
§ Hypertension monitoring; 
o Clinical tests and CAD detection algorithm validation with angiography; 
• Business aspects 
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o Business model clarification and creation of the financing plan; 
o Researching initial investment opportunities; 
o Evaluation of the social aspects, skepticism and cornerstones for 
personalized medicine; 
o Investigation of medical data handling regulations; 
o Market expansion, partners and early adopters; 
o Regulations, clinical tests and certifications. 
Currently, product is designed to be ubiquitous and multifaceted, as the idea of the project 
was born due to the lack of a tool that is necessary for doctors, patients, company leaders 
or healthcare system workers. It may happen that future work on Lub.dapp would 
dramatically squeeze the set of features, targeted cardiovascular conditions and target 
final applications, however now the vision for centralized CVD management system is 
prevalent. 
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CONCLUSION 
Cardiology with no doubt is a big market segment for medical technologies startups in 
Finland and all over the world. This area offers a wide variety of open questions to tackle. 
As shown on the example of phonocardiography appliance for coronary artery disease 
diagnosing and heart monitoring, truly personal services design is possible even in 
medical applications. Hopefully, this trend in modern healthcare will develop and in the 
nearest future such devices will be incorporated into usual healthy life rhythm, leading to 
fully personal predictive medicine. Of course, such change is not possible on local levels 
only, so public and private investors, designers, technological experts and businesses 
should tightly work together to gear the evolution. 
If we evaluate the initial research question, the concise findings are the following: 
• Medical technologies could transform the vision on healthcare, shifting the focus 
from treatment in evidence-based medicine paradigm to prevention in prediction 
medicine paradigm. For example, heart monitoring opens a possibility to detect 
CAD, MI, arrhythmias and hypertension on early stages, what minimizes the 
heaviness of the disease flow; 
• No single CVD could be accentuated, as human’s cardiovascular system is a 
complex mechanism. Different conditions are caused by the same factors and 
often develop from one to another. Coronary artery disease, arrhythmias and 
hypertension were selected as the target conditions as the most prior and frequent; 
• Phonography is one of the most promising methods for heart monitoring and 
diagnosing. It was used to analyze CAD audial signature in the given product 
example. Of course, this method requires a lot of clinical testing and technological 
optimization but already on early phases it shows applicable results; 
• Proper user interface and device design are the task of paramount importance to 
drive the healthcare change. Current technologies already allow us to build highly 
accurate sensors and powerful data analysis algorithms. All of the research 
organizations are working on it, while the user-oriented design needs are blurred, 
consequently that issue is also critical today; 
 
 
 
76 
• Standalone devices and applications are not efficient. Medical product should 
provide a service to the customer and unite all the involved members in the single 
centralized ecosystem; 
• Adults are the major target auditory for the cardiological devices; 
• Finland and Nordic countries are the most applicable regions for new medical 
gadget piloting, based on the environmental characteristics and economics. 
The initial idea of Lub.dapp system enlarged dramatically during the topic research 
process. Moreover, its product positioning, functional set and motivation have been 
transformed. The final result could be used as a foundation for the future work on the 
product delivery. To summarize, all the planned for this study product deliverables are 
met, while new growth vectors are outlined to proceed on the system advancement and 
potential manufacturing. 
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Question 1: What is your vision on the healthcare approach transformation towards predictive 
personalized digital methods? Do you believe that some of the existing professional diagnosis 
and monitoring cardiac devices, especially those using acoustic detection, could be modified 
and adapted for the consumer use? What limitations and possible development barriers do you 
see? 
Answer 1: “Digital methods will contribute to the concept of personalized medicine as all 
other methods. It is the blend the doctor uses for his patients. Clear diagnosis and treatment 
pathways are needed. Consumer use means typically “screening” which is a risky thing for 
diagnostic methods, as you risk sending “false positive” patients further into diagnostics they 
don’t need. In most cases symptoms shall lead the diagnostic pathway and this should be in 
professional, not lay hands.” 
 
Question 2: What is your vision on patient’s scepticism about modern technologies in 
cardiology? 
Answer 2: “Such skepticism is not a matter of cardiology only but a symptom of lost trust in 
our health care systems, in which the holistic view on patients often is replaced by technical 
medicine. The change is a health political / society issue, not a technological. In eastern 
countries holistic treatment of patients and modern medicine go very well hand in hand.” 
 
Question 3: Have you ever been evaluating the possibility and the need to prepare a consumer 
version of Acarix CADScor®System to be used in the ecosystem which connects patient and 
his/her cardiologist? If you find it irrelevant, why do you think so? 
Answer 3: “This is irrelevant as the “screening” usage of CADScor®System bears high risks 
of “overdiagnosing” patients without symptoms. The system intends to rule out symptomatic 
patients, as many chest pain patients don’t suffer from CAD but from issues in back and neck, 
stomach etc.” 
 
Question 4: Would it be interesting to some certain degree for Acarix to partner with smaller 
company to make a consumer-oriented product using your expertise in technology and partner’s 
business model and product vision (mobile application, platform, device design) for consumer-
oriented distribution? 
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Answer 4: “As we are still in an early phase we are focusing on our own development. Of 
course, we are always open for ideas that could create synergy and support our own scaling, 
but it is not an active part of our organization.”  
 
Question 5: What do you think about medical technologies market in Nordics today and how 
would you estimate it’s changes in the next 5 years? In your opinion, is there a segment for the 
new small organizations or everything is centralized on the enterprise players and highly 
specific companies like Acarix? 
Answer 5: “This is a health political question and depends if health care shall be centralized 
by the state more and more or not. We expect to be a standard diagnostic aid in the future and 
recommended in clinical guidelines one day. If the sales process is centralized or decentralized 
is a matter of organizational evolution. We will adapt to the environment here but not creating 
it.” 
 
Question 6: What are the perspectives of acoustic detection in terms of another cardiovascular 
conditions, apart from CAD? Are you interested in the research towards new diagnosis 
techniques and what directions do you find the most perspective? 
Answer 6: “Yes, we develop new diagnostic fields but this a confidential matter at this point 
in time.” 
 
 
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 85 
 
Screen 1 Screen 2 Screen 3 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 86 
 
Screen 4 Screen 5 Screen 6 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 87 
 
Screen 7 Screen 8 Screen 9 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 88 
 
Screen 10 Screen 11 Screen 12 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 89 
 
Screen 13 Screen 14 Screen 15 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 90 
 
Screen 16 Screen 17 Screen 18 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 91 
 
Screen 19 Screen 20 Screen 21 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 92 
 
Screen 22 Screen 23 Screen 24 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 93 
 
Screen 25 Screen 26 Screen 27 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 94 
 
Screen 28 Screen 29 Screen 30 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 95 
 
Screen 31 Screen 32 Screen 33 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 96 
 
Screen 34 Screen 35 Screen 36 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 97 
 
Screen 37 Screen 38 Screen 39 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 98 
 
Screen 40 Screen 41 Screen 42 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 99 
 
Screen 43 Screen 44 Screen 45 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 100 
 
Screen 46 Screen 47 Screen 48 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 101 
 
Screen 49 Screen 50 Screen 51 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 102 
 
Screen 52 Screen 53 Screen 54 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 103 
 
Screen 55 Screen 56 Screen 57 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 104 
 
Screen 58 Screen 59 Screen 60 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 105 
 
Screen 61 Screen 62 Screen 63 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 106 
 
Screen 64 Screen 65 Screen 66 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 107 
 
Screen 67 Screen 68 Screen 69 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 108 
 
Screen 70 Screen 71 Screen 72 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 109 
 
Screen 73 Screen 74 Screen 75 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 110 
 
Screen 76 Screen 77 Screen 78 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 111 
 
Screen 79 Screen 80 Screen 81 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 112 
 
Screen 82 Screen 83 Screen 84 
   
APPENDIX 2 
Lubdapp mobile application – iOS interfaces design 
 113 
 
Screen 85   
 
  
APPENDIX 3 
Lubdapp watch application – WatchOS interfaces design 
 114 
 
Screen 1 Screen 2 Screen 3 Screen 4 
    
 
Screen 5 
 
Screen 6 
 
Screen 7 
 
Screen 8 
    
 
APPENDIX 3 
Lubdapp watch application – WatchOS interfaces design 
 115 
 
Screen 9 Screen 10 Screen 11 Screen 12 
    
 
Screen 13 
 
Screen 14 
 
Screen 15 
 
Screen 16 
    
 
APPENDIX 3 
Lubdapp watch application – WatchOS interfaces design 
 116 
 
Screen 17 Screen 18 Screen 19 Screen 20 
    
    
    
 
 
 
 
 
 
 
 
APPENDIX 4 
Thesis mind map: components, flow and milestones 
 117 
 
 
 
 
